<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK154378" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK154378/" /><meta name="ncbi_pagename" content="Ornithine Transcarbamylase Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ornithine Transcarbamylase Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Ornithine Transcarbamylase Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/04/14" /><meta name="citation_author" content="Uta Lichter-Konecki" /><meta name="citation_author" content="Ljubica Caldovic" /><meta name="citation_author" content="Hiroki Morizono" /><meta name="citation_author" content="Kara Simpson" /><meta name="citation_pmid" content="24006547" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK154378/" /><meta name="citation_keywords" content="Ornithine Carbamoyltransferase Deficiency" /><meta name="citation_keywords" content="OTC Deficiency" /><meta name="citation_keywords" content="OTC Deficiency" /><meta name="citation_keywords" content="Ornithine Carbamoyltransferase Deficiency" /><meta name="citation_keywords" content="Ornithine carbamoyltransferase, mitochondrial" /><meta name="citation_keywords" content="OTC" /><meta name="citation_keywords" content="Ornithine Transcarbamylase Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ornithine Transcarbamylase Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Uta Lichter-Konecki" /><meta name="DC.Contributor" content="Ljubica Caldovic" /><meta name="DC.Contributor" content="Hiroki Morizono" /><meta name="DC.Contributor" content="Kara Simpson" /><meta name="DC.Date" content="2016/04/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK154378/" /><meta name="description" content="Ornithine transcarbamylase (OTC) deficiency can occur as a severe neonatal-onset disease in males (but rarely in females) and as a post-neonatal-onset (partial deficiency) disease in males and females. Males with severe neonatal-onset OTC deficiency are typically normal at birth but become symptomatic from hyperammonemia on day two to three of life and are usually catastrophically ill by the time they come to medical attention. After successful treatment of neonatal hyperammonemic coma these infants can easily become hyperammonemic again despite appropriate treatment; they typically require liver transplant by age six months to improve quality of life. Males and heterozygous females with post-neonatal-onset (partial) OTC deficiency can present from infancy to later childhood, adolescence, or adulthood. No matter how mild the disease, a hyperammonemic crisis can be precipitated by stressors and become a life-threatening event at any age and in any situation in life. For all individuals with OTC deficiency, typical neuropsychological complications include developmental delay, learning disabilities, intellectual disability, attention deficit hyperactivity disorder (ADHD), and executive function deficits." /><meta name="og:title" content="Ornithine Transcarbamylase Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="Ornithine transcarbamylase (OTC) deficiency can occur as a severe neonatal-onset disease in males (but rarely in females) and as a post-neonatal-onset (partial deficiency) disease in males and females. Males with severe neonatal-onset OTC deficiency are typically normal at birth but become symptomatic from hyperammonemia on day two to three of life and are usually catastrophically ill by the time they come to medical attention. After successful treatment of neonatal hyperammonemic coma these infants can easily become hyperammonemic again despite appropriate treatment; they typically require liver transplant by age six months to improve quality of life. Males and heterozygous females with post-neonatal-onset (partial) OTC deficiency can present from infancy to later childhood, adolescence, or adulthood. No matter how mild the disease, a hyperammonemic crisis can be precipitated by stressors and become a life-threatening event at any age and in any situation in life. For all individuals with OTC deficiency, typical neuropsychological complications include developmental delay, learning disabilities, intellectual disability, attention deficit hyperactivity disorder (ADHD), and executive function deficits." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK154378/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/otc-def/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK154378/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B54BBE03FB6F10000000006A90268.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK154378_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK154378_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ofd1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/chrom17-lis/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK154378_"><span class="title" itemprop="name">Ornithine Transcarbamylase Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Ornithine Carbamoyltransferase Deficiency, OTC Deficiency</div><p class="contrib-group"><span itemprop="author">Uta Lichter-Konecki</span>, MD, PhD, <span itemprop="author">Ljubica Caldovic</span>, PhD, <span itemprop="author">Hiroki Morizono</span>, PhD, and <span itemprop="author">Kara Simpson</span>, MS, CGC.</p><a data-jig="ncbitoggler" href="#__NBK154378_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK154378_ai__"><div class="contrib half_rhythm"><span itemprop="author">Uta Lichter-Konecki</span>, MD, PhD<div class="affiliation small">Section of Child Neurology<br />St. Christopher's Hospital for Children<br />Department of Pediatrics<br />Drexel University College of Medicine<br />Philadelphia, PA<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.demlexerd@rethcilu" class="oemail">ude.demlexerd@rethcilu</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Ljubica Caldovic</span>, PhD<div class="affiliation small">Center for Genetic Research<br />Children's National Medical Center<br />Washington, DC</div></div><div class="contrib half_rhythm"><span itemprop="author">Hiroki Morizono</span>, PhD<div class="affiliation small">Center for Genetic Research<br />Children's National Medical Center<br />Washington, DC</div></div><div class="contrib half_rhythm"><span itemprop="author">Kara Simpson</span>, MS, CGC<div class="affiliation small">Division of Genetics &#x00026; Metabolism<br />Children's National Medical Center<br />Washington, DC</div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 29, 2013</span>; Last Update: <span itemprop="dateModified">April 14, 2016</span>.</p><p><em>Estimated reading time: 41 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="otc-def.Summary" itemprop="description"><h2 id="_otc-def_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Ornithine transcarbamylase (OTC) deficiency can occur as a severe neonatal-onset disease in males (but rarely in females) and as a post-neonatal-onset (partial deficiency) disease in males and females. Males with severe neonatal-onset OTC deficiency are typically normal at birth but become symptomatic from hyperammonemia on day two to three of life and are usually catastrophically ill by the time they come to medical attention. After successful treatment of neonatal hyperammonemic coma these infants can easily become hyperammonemic again despite appropriate treatment; they typically require liver transplant by age six months to improve quality of life. Males and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females with post-neonatal-onset (partial) OTC deficiency can present from infancy to later childhood, adolescence, or adulthood. No matter how mild the disease, a hyperammonemic crisis can be precipitated by stressors and become a life-threatening event at any age and in any situation in life. For all individuals with OTC deficiency, typical neuropsychological complications include developmental delay, learning disabilities, intellectual disability, attention deficit hyperactivity disorder (ADHD), and executive function deficits.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of OTC deficiency is established in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive clinical and laboratory findings and/or at least ONE of the following:</p><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>OTC</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a></div></li><li class="half_rhythm"><div>A markedly abnormal increase of orotic acid excretion after an allopurinol challenge test</div></li><li class="half_rhythm"><div>Decreased OTC enzyme activity in liver</div></li></ul><p>The diagnosis of OTC deficiency is usually established in a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the suggestive clinical and laboratory findings and/or with at least ONE of the following:</p><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>OTC</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a></div></li><li class="half_rhythm"><div>A markedly abnormal increase of orotic acid excretion after an allopurinol challenge test</div></li></ul><p>Measurement of OTC enzyme activity in liver is not a reliable means of diagnosis in females.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment is best provided by a clinical geneticist and a nutritionist experienced in the treatment of metabolic disease; treatment of hyperammonemic coma should be provided by a team coordinated by a metabolic specialist in a tertiary care center experienced in the management of OTC deficiency. The mainstays of treatment of the acute phase are rapid lowering of the plasma ammonia level to &#x02264;200 &#x003bc;mol/L (if necessary, with renal replacement therapy); use of ammonia scavenger treatment to allow excretion of excess nitrogen via alternative pathways; reversal of catabolism; and reducing the risk of neurologic damage. The goals of long-term treatment are to promote growth and development and to prevent hyperammonemic episodes. In severe, neonatal-onset urea cycle disorders, liver transplantation is typically performed by age six months to prevent further hyperammonemic crises and neurodevelopmental deterioration. In females and males with partial OTC deficiency liver transplant is typically considered in those who have frequent hyperammonemic episodes. Complications of OTC deficiency, including ADHD and learning disability/intellectual disability, are treated according to the standard of care for these conditions while monitoring for signs of liver disease.</p><p><i>Prevention of primary manifestations:</i> If neonatal-onset OTC deficiency is diagnosed prenatally, intravenous (IV) treatment with ammonia scavengers within a few hours of birth (before the ammonia level rises) can prevent a hyperammonemic crisis and coma. For preventive measures after the neonatal period see <i>Treatment of manifestations</i>.</p><p><i>Prevention of secondary complications:</i> Avoid overrestriction of protein/amino acids; use gastrostomy tube feedings as needed to help avoid malnutrition; practice careful hand hygiene among all who have contact with the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual to minimize risk of infection; give immunizations on the usual schedule, including annual flu vaccine; provide multivitamin and vitamin D supplementation; and use antipyretics appropriately (e.g., ibuprofen is preferred over acetaminophen because of the potential for liver toxicity).</p><p><i>Surveillance:</i> At the start of therapy, routine measurement of plasma ammonia and plasma amino acids. Assess liver function (depending on symptoms) every three to six months or more often when previously abnormal. Perform neuropsychological testing at the time of expected significant developmental milestones.</p><p><i>Agents/circumstances to avoid:</i> Valproate, haloperidol, systemic corticosteroids, fasting, and physical and psychological stress.</p><p><i>Evaluation of relatives at risk:</i> If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known and if prenatal testing has not been performed, it is appropriate to perform biochemical and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> on at-risk newborns (males and females) as soon after birth as possible so that the appropriate treatment or surveillance (for those with the family-specific pathogenic variant) can be promptly established. If the pathogenic variant in the family is NOT known, biochemical analysis (plasma amino acid analysis, ammonia level), an allopurinol challenge test (in older individuals), and/or OTC enzyme activity measurement in liver (males only) can be performed. Preventive measures at birth should be instituted until such a time as the diagnosis can be ruled out.</p><p><i>Pregnancy management:</i> Heterozygous females are at risk of becoming catabolic during pregnancy and especially in the postpartum period. Those who are symptomatic need to be treated throughout pregnancy as necessary; those who are asymptomatic need to avoid catabolism in the peripartum and postpartum periods and should be treated as needed.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>OTC deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. If an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male reproduces, none of his sons will be affected and all of his daughters will inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and may or may not develop clinical symptoms related to the disorder. Heterozygous females have a 50% chance of transmitting the pathogenic variant with each pregnancy: males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant may or may not develop clinical findings related to the disorder. Carrier testing for females at risk of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> and prenatal testing for pregnancies at increased risk are possible if the <i>OTC</i> pathogenic variant has been identified in an affected family member.</p></div></div><div id="otc-def.Diagnosis"><h2 id="_otc-def_Diagnosis_">Diagnosis</h2><p>Diagnostic criteria for ornithine transcarbamylase (OTC) deficiency have been set forth by the Urea Cycle Disorders Consortium of the Rare Disease Clinical Research Network [<a class="bk_pop" href="#otc-def.REF.tuchman.2008.397">Tuchman et al 2008</a>].</p><div id="otc-def.Suggestive_Findings"><h3>Suggestive Findings</h3><p>OTC deficiency <b>should be suspected</b> in an individual with the following <a href="#otc-def.Clinical_Features">clinical features</a> (by sex/age), <a href="#otc-def.Family_History">family history</a>, and <a href="#otc-def.Supportive_Laboratory_Findings">supportive laboratory findings</a>:</p><div id="otc-def.Clinical_Features"><h4>Clinical Features</h4><p><b>Term newborn male</b></p><ul><li class="half_rhythm"><div>Normal at birth</div></li><li class="half_rhythm"><div>Development of reduced oral intake with poor latching and suck</div></li><li class="half_rhythm"><div>Acute neonatal encephalopathy (lethargy, somnolence) with hyperventilation and low body temperature</div></li></ul><p><b>Child, adolescent, or adult</b>
<b>(male or female)</b></p><ul><li class="half_rhythm"><div>Encephalopathic or psychotic episodes (i.e., episodes of altered mental status), including erratic behavior, clouded consciousness, and delirium</div></li><li class="half_rhythm"><div>A recent stress that could be regarded as a precipitating event (e.g., significant change in diet, significant medical problem including illness or accident, delivery, systemic use of corticosteroids or valproate)</div></li><li class="half_rhythm"><div>History of recurrent vomiting</div></li><li class="half_rhythm"><div>Migraine headaches</div></li><li class="half_rhythm"><div>Reye-like syndrome</div></li><li class="half_rhythm"><div>Seizures</div></li><li class="half_rhythm"><div>History of true protein avoidance (avoidance of not only red meat but also of milk, eggs, other high-protein foods)</div></li><li class="half_rhythm"><div>Unexplained "cerebral palsy"</div></li></ul></div><div id="otc-def.Family_History"><h4>Family History</h4><p>Death of newborn males (related through females in a manner consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance) in the first week of life from "sepsis" or with unexplained somnolence, refusal to feed, tachypnea, and catastrophic illness is suggestive of OTC deficiency.</p><p>Note: Absence of a family history of individuals with similar episodes does not preclude the diagnosis.</p></div><div id="otc-def.Supportive_Laboratory_Findings"><h4>Supportive Laboratory Findings</h4><p><b>Newborn screening (NBS).</b> OTC deficiency is universally screened for in Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont, and likely to be detected in Kentucky (see <a href="https://data.newsteps.org/newsteps-web/reports/screenedConditions/list.action" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">data.newsteps.org</a>).</p><ul><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> and specificity of a low citrulline level as a marker for OTC deficiency in NBS has been questioned; however, the false positive rate in Minnesota has matched the average performance of primary analytes for conditions detected by tandem mass spectroscopy (MS/MS) on NBS [<a class="bk_pop" href="#otc-def.REF.hall.2014.889">Hall et al 2014</a>].</div></li><li class="half_rhythm"><div>The detection of OTC deficiency on NBS may be improved by using the <a href="https://clir.mayo.edu/Home/About" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Collaborative Laboratory Integrated Reports</a> (CLIR), an interactive web tool that includes glutamine, glutamate, and amino acid ratios (e.g., citrulline-to-glycine ratio) in the analysis.</div></li></ul><p><b>Plasma ammonia concentration.</b> During acute encephalopathy, ammonia levels are typically above 200 &#x003bc;mol/L and often above 500-1,000 &#x003bc;mol/L.</p><p>Note: The plasma ammonia concentration at which an individual becomes symptomatic varies but is generally above 100 &#x003bc;mol/L; in stage 2 coma [<a class="bk_pop" href="#otc-def.REF.plum.1982">Plum &#x00026; Posner 1982</a>] the plasma concentration may be between 200 and 400 &#x003bc;mol/L; and in stage 3 to 4 coma, above 500 &#x003bc;mol/L. These levels are approximations and a wider range of elevated ammonia levels may be observed.</p><p><b>Plasma amino acid analysis.</b> A high glutamine concentration (generally &#x0003e;800 &#x003bc;mol/L) and a (very) low citrulline concentration (e.g., single digits, with or without elevated plasma ammonia concentration) is suggestive of a proximal urea cycle defect, such as N-acetylglutamate synthetase (NAGS) deficiency, carbamoyl phosphate synthetase I (CPSI) deficiency, or OTC deficiency.</p><p><b>Urine organic acid (UOA) analysis.</b> Orotic acid concentration is elevated in a random urine sample (e.g., &#x0003e;20 &#x003bc;mol/mmol creatinine if the laboratory provides quantitative values).</p><p><b>Blood gases</b></p><ul><li class="half_rhythm"><div>Respiratory alkalosis in an encephalopathic individual who is hyperventilating is pathognomonic of urea cycle disorders [<a class="bk_pop" href="#otc-def.REF.maestri.1999.268">Maestri et al 1999</a>].</div></li><li class="half_rhythm"><div>In a terminally ill individual who has been in a coma for days, acidosis may develop.</div></li></ul></div></div><div id="otc-def.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of OTC deficiency <b>is established</b> in a male proband with the above clinical and laboratory findings and/or with at least ONE of the following:</p><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>OTC</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK154378/table/otc-def.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figotcdefTmoleculargenetictestingused" rid-ob="figobotcdefTmoleculargenetictestingused">Table 1</a>)</div></li><li class="half_rhythm"><div>A markedly abnormal increase of orotic acid excretion after an allopurinol challenge test (see <b>Allopurinol challenge test</b> below) with or without a family history of OTC deficiency [<a class="bk_pop" href="#otc-def.REF.tuchman.2008.397">Tuchman et al 2008</a>]</div></li><li class="half_rhythm"><div>Decreased OTC enzyme activity in liver (see <b>OTC enzyme activity in liver</b> below)</div></li></ul><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of OTC deficiency <b>is usually established</b> in a female proband with the above <a href="#otc-def.Clinical_Features">clinical features</a> and <a href="#otc-def.Supportive_Laboratory_Findings">supportive laboratory findings</a> and/or with at least ONE of the following: a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>OTC</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK154378/table/otc-def.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figotcdefTmoleculargenetictestingused" rid-ob="figobotcdefTmoleculargenetictestingused">Table 1</a>) or a markedly abnormal increase of orotic acid excretion after an allopurinol challenge test (see <b>Allopurinol challenge test</b>) with or without a family history of OTC deficiency.</p><p>Note: Liver biopsy is not recommended to establish the diagnosis in females (see <b>OTC enzyme activity in liver</b>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>OTC</i> is performed first.</p><ul><li class="half_rhythm"><div>In a male, lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> should prompt <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</div></li><li class="half_rhythm"><div>In a female in whom <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> does not reveal a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> should be performed next.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>OTC</i> and other genes of interest (see <a href="#otc-def.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="otc-def.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Ornithine Transcarbamylase (OTC) Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154378/table/otc-def.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__otc-def.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>OTC</i></td><td headers="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4,&#x000a0;5</sup></td><td headers="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%-80%&#x000a0;<sup>6,&#x000a0;7</sup></td></tr><tr><td headers="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> &#x00026; complex rearrangements&#x000a0;<sup>8</sup></td><td headers="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%-10%&#x000a0;<sup>9,&#x000a0;10,&#x000a0;11</sup></td></tr><tr><td headers="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>12</sup></td><td headers="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_otc-def.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="otc-def.TF.1.1"><p class="no_margin">See <a href="/books/NBK154378/#otc-def.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="otc-def.TF.1.2"><p class="no_margin">See <a href="#otc-def.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="otc-def.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="otc-def.TF.1.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="otc-def.TF.1.5"><p class="no_margin">Sequencing of <i>OTC</i> regulatory regions can be used to screen for pathogenic variants in the <i>OTC</i> promoter and enhancer [<a class="bk_pop" href="#otc-def.REF.luksan.2010.e1294">Luksan et al 2010</a>]. See <a href="#otc-def.Molecular_Genetics">Molecular Genetics</a>.</p></div></dd><dt>6. </dt><dd><div id="otc-def.TF.1.6"><p class="no_margin">In individuals with biochemically confirmed OTC deficiency (i.e., elevated urinary orotate, a positive allopurinol test, reduced OTC enzyme activity in liver biopsy, or a combination of these findings) [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>]</p></div></dd><dt>7. </dt><dd><div id="otc-def.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#otc-def.REF.bailly.2015.e146">Bailly et al [2015]</a>, <a class="bk_pop" href="#otc-def.REF.choi.2015.501">Choi et al [2015]</a>, <a class="bk_pop" href="#otc-def.REF.mohamed.2015.1229">Mohamed et al [2015]</a>, <a class="bk_pop" href="#otc-def.REF.prasun.2015.782">Prasun et al [2015]</a></p></div></dd><dt>8. </dt><dd><div id="otc-def.TF.1.8"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>9. </dt><dd><div id="otc-def.TF.1.9"><p class="no_margin">When <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> was followed by <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> a molecular defect was detected in 80%-90% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with biochemically confirmed OTC deficiency [<a class="bk_pop" href="#otc-def.REF.tuchman.1998.40">Tuchman et al 1998</a>, <a class="bk_pop" href="#otc-def.REF.shchelochkov.2009.97">Shchelochkov et al 2009</a>, <a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>].</p></div></dd><dt>10. </dt><dd><div id="otc-def.TF.1.10"><p class="no_margin">Large deletions, duplications, and chromosomal rearrangements that encompass parts or all of <i>OTC</i> as well as neighboring genes have been detected using <a class="def" href="/books/n/gene/glossary/def-item/cytogenetic/">cytogenetic</a> and molecular genetic techniques (see <a href="#otc-def.Genetically_Related_Allelic_Diso">Genetically Related Disorders</a> and <a href="#otc-def.Molecular_Genetics">Molecular Genetics</a>) [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.choi.2015.501">Choi et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.di_stefano.2015.203">Di Stefano et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.gallant.2015.249">Gallant et al 2015</a>].</p></div></dd><dt>11. </dt><dd><div id="otc-def.TF.1.11"><p class="no_margin">Synthesis and sequencing of <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> from illegitimate transcripts isolated from fibroblasts or from transcripts isolated from liver biopsy specimens has been used to detect pathogenic variants that create novel splice sites leading to aberrant <i>OTC</i> transcripts [<a class="bk_pop" href="#otc-def.REF.h_berle.2003.649">H&#x000e4;berle &#x00026; Koch 2003</a>, <a class="bk_pop" href="#otc-def.REF.engel.2008.292">Engel et al 2008</a>].</p></div></dd><dt>12. </dt><dd><div id="otc-def.TF.1.12"><p class="no_margin">Because an estimated 10%-20% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have no detectable <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> heterogeneity cannot be excluded.</p></div></dd></dl></div></div></div><p><b>Allopurinol challenge test.</b> In males and females suspected of having partial OTC deficiency who have normal <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> and normal or borderline urinary orotic acid concentration under normal conditions, an allopurinol challenge test should be performed. A markedly abnormal increase of orotic acid excretion after administering allopurinol is diagnostic [<a class="bk_pop" href="#otc-def.REF.burlina.1992.707">Burlina et al 1992</a>, <a class="bk_pop" href="#otc-def.REF.oexle.2006a.204">Oexle 2006a</a>, <a class="bk_pop" href="#otc-def.REF.oexle.2006b.241">Oexle 2006b</a>, <a class="bk_pop" href="#otc-def.REF.gr_newald.2004.179">Gr&#x000fc;newald et al 2004</a>]. The test consists of taking a single dose of allopurinol and immediately thereafter starting to collect urine during four six-hour periods for a total of 24 hours. Aliquots from each six-hour period are analyzed for orotic acid concentration.</p><p><b>OTC enzyme activity in liver.</b> Previously the gold standard for diagnosing OTC deficiency [<a class="bk_pop" href="#otc-def.REF.tuchman.1989.77">Tuchman et al 1989</a>], analysis of OTC enzyme activity in liver requires a liver biopsy, and thus is currently used only when an <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not found in a male with a high clinical suspicion of OTC deficiency or if an allopurinol challenge is inconclusive.</p><ul><li class="half_rhythm"><div><b>Males.</b> In severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males, OTC enzyme activity is typically less than 20% of the control value. In milder OTC deficiency, enzymatic activity may be as high as 30% of the control value.</div></li><li class="half_rhythm"><div><b>Females.</b> Results of enzyme activity analysis in a liver biopsy may not represent the true total OTC activity in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female because of the <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> pattern (previously known as lyonization) in the biopsy specimen (see Clinical Description, <a href="#otc-def.Heterozygous_Females">Heterozygous Females</a>).</div></li></ul></div></div><div id="otc-def.Clinical_Characteristics"><h2 id="_otc-def_Clinical_Characteristics_">Clinical Characteristics</h2><div id="otc-def.Clinical_Description"><h3>Clinical Description</h3><p>Ornithine transcarbamylase (OTC) deficiency can occur as a severe neonatal-onset disease in males and as a post-neonatal-onset (partial deficiency) disease in males and females. Neonatal-onset disease in females is very rare.</p><p>Although neonatal-onset ornithine transcarbamylase (OTC) deficiency accounted for approximately 60% of all OTC deficiency in the older literature [<a class="bk_pop" href="#otc-def.REF.matsuda.1991.85">Matsuda et al 1991</a>], the longitudinal study of the Urea Cycle Disorders Consortium (UCDC) of the NICHD-supported Rare Disease Clinical Research Network (RDCRN) has enrolled to date a substantially smaller proportion of individuals with neonatal-onset OTC deficiency than with post-neonatal-onset OTC deficiency. Of 260 individuals who had symptomatic OTC deficiency, 47 (18%) had neonatal-onset disease (42 males and 5 females) and 213 (82%) had post-neonatal onset disease (154 females and 59 males) [<a class="bk_pop" href="#otc-def.REF.batshaw.2014.127">Batshaw et al 2014</a>].</p><div id="otc-def.NeonatalOnset_OTC_Deficiency"><h4>Neonatal-Onset OTC Deficiency</h4><p>Males with severe OTC deficiency are typically normal at birth, but become symptomatic on the second to third day of life with poor suck, reduced intake, and hypotonia, followed by lethargy progressing to somnolence and coma. They hyperventilate, and may have seizures. By the time neonates with OTC deficiency come to medical attention they typically are catastrophically ill with low body temperature (hypothermia), severe encephalopathy, and respiratory alkalosis.</p><p>When clinical and laboratory findings support the diagnosis of a urea cycle disorder, rescue therapy is begun immediately (see Management, <a href="#otc-def.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p><p>The prognosis of a newborn in hyperammonemic coma depends on the duration of elevated ammonia level, not the height of the ammonia level or the presence or absence of seizures [<a class="bk_pop" href="#otc-def.REF.msall.1984.1500">Msall et al 1984</a>].</p><p>After successful rescue from neonatal hyperammonemic coma, infants with severe neonatal-onset OTC deficiency can easily become hyperammonemic again despite a low-protein diet and treatment with an oral ammonia scavenger. Even on maximum ammonia scavenger therapy a neonate with severe OTC deficiency may only tolerate 1.5 g/kg/day of protein (the minimum amount needed to grow), and growth may be along the third percentile for length.</p><p>After neonatal rescue therapy, a child with severe neonatal-onset disease can also experience a "honeymoon" period in which the protein tolerance is so high, due to rapid growth, that the child is metabolically stable for some months before experiencing frequent hyperammonemic episodes.</p><p>Typically by age six months (if not sooner) a liver transplant is needed because of the effect of recurrent hyperammonemia on the brain and of prolonged hospitalizations on quality of life.</p><p>The overall outcome depends on the severity of brain damage during the initial hyperammonemic crisis and during subsequent hyperammonemic crises, as well as on the success of long-term treatment in maintaining metabolic balance and treating complications of the disease.</p></div><div id="otc-def.PostNeonatalOnset_Partial_OTC_De"><h4>Post-Neonatal-Onset (Partial) OTC Deficiency</h4><p>Hemizygous males and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females with partial OTC deficiency can present from infancy to later childhood, adolescence, or adulthood [<a class="bk_pop" href="#otc-def.REF.ahrens.1996.311">Ahrens et al 1996</a>, <a class="bk_pop" href="#otc-def.REF.ausems.1997.236">Ausems et al 1997</a>, <a class="bk_pop" href="#otc-def.REF.mccullough.2000.313">McCullough et al 2000</a>]. Often they first become symptomatic in infancy when switched from breast milk to formula or whole milk (breast milk contains less protein than infant formulas manufactured in the US). Infants may show episodic vomiting, lethargy, irritability, failure to thrive, and developmental delay. They show true protein avoidance, which can be documented by a detailed assessment of their dietary intake. When forced to eat high-protein-content food, they may become symptomatic.</p><p>A stressor can cause an individual with partial OTC deficiency to become symptomatic at any age. In general the milder the disease, the later the onset and the stronger the stressor required to precipitate symptoms.</p><p>Adults with very mild disease have become symptomatic after crush injury, post-operatively [<a class="bk_pop" href="#otc-def.REF.chiong.2007.418">Chiong et al 2007</a>, <a class="bk_pop" href="#otc-def.REF.hu.2007.126">Hu et al 2007</a>], when on a high-protein diet (e.g., Atkins diet [<a class="bk_pop" href="#otc-def.REF.benari.2010.292">Ben-Ari et al 2010</a>]), during the postpartum period (see <a href="#otc-def.Pregnancy_Management">Pregnancy Management</a>), during cancer therapy, after prolonged fasting [<a class="bk_pop" href="#otc-def.REF.marcus.2008.395">Marcus et al 2008</a>], when treated with high-dose systemic corticosteroids [<a class="bk_pop" href="#otc-def.REF.lipskind.2011.682">Lipskind et al 2011</a>], or after a febrile illness [<a class="bk_pop" href="#otc-def.REF.panlaqui.2008.1922">Panlaqui et al 2008</a>]. Treatment with valproate [<a class="bk_pop" href="#otc-def.REF.morgan.1987.886">Morgan et al 1987</a>, <a class="bk_pop" href="#otc-def.REF.arn.1990.1652">Arn et al 1990</a>, <a class="bk_pop" href="#otc-def.REF.honeycutt.1992.666">Honeycutt et al 1992</a>] or haloperidol has been associated with hyperammonemic crises in persons with OTC deficiency [<a class="bk_pop" href="#otc-def.REF.rubenstein.1990.754">Rubenstein et al 1990</a>, <a class="bk_pop" href="#otc-def.REF.le_o.1995.593">Le&#x000e3;o 1995</a>, <a class="bk_pop" href="#otc-def.REF.oechsner.1998.680">Oechsner et al 1998</a>, <a class="bk_pop" href="#otc-def.REF.thakur.2006.273">Thakur et al 2006</a>].</p><p>When children, adolescents, or adults with post-neonatal-onset disease become encephalopathic they may reach stage 2 coma [<a class="bk_pop" href="#otc-def.REF.plum.1982">Plum &#x00026; Posner 1982</a>] with erratic behavior, combativeness, and delirium (e.g., not recognizing family members around them, unintelligible speech). They may come to medical attention if these behavioral abnormalities lead to an emergency medical or psychiatric evaluation.</p></div><div id="otc-def.Heterozygous_Females"><h4>Heterozygous Females</h4><p>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female can range from asymptomatic to significant symptoms with recurrent hyperammonemia and neurologic compromise depending on favorable vs non-favorable <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>. The amount of OTC enzyme activity in the liver of a heterozygous female depends on the pattern of X-chromosome inactivation in her liver [<a class="bk_pop" href="#otc-def.REF.yorifuji.1998.349">Yorifuji et al 1998</a>]. Thus, a heterozygous female can manifest symptoms of OTC deficiency if X-chromosome inactivation in her liver cells is skewed such that the X chromosome with the pathogenic <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is active in more hepatocytes than the X chromosome with the wild type <i>OTC</i> allele [<a class="bk_pop" href="#otc-def.REF.ricciuti.1976.332">Ricciuti et al 1976</a>, <a class="bk_pop" href="#otc-def.REF.mccullough.2000.313">McCullough et al 2000</a>, <a class="bk_pop" href="#otc-def.REF.yamaguchi.2006.626">Yamaguchi et al 2006</a>].</p><p>Previously, approximately 15% of <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females were thought to become symptomatic during their lifetime [<a class="bk_pop" href="#otc-def.REF.batshaw.1986.236">Batshaw et al 1986</a>]. Many heterozygous females exhibit mild symptoms, self-restrict protein intake, and are never diagnosed as being symptomatic. The diagnosis may only be revealed when a more severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child is born, prompting <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in the mother. Thus, the percent of symptomatic females may be higher than previously thought. When a male has post-neonatal-onset disease, the risk for symptoms in heterozygous females in his family is much lower than in families in which a male has neonatal-onset severe disease [<a class="bk_pop" href="#otc-def.REF.mccullough.2000.313">McCullough et al 2000</a>].</p></div><div id="otc-def.Complications_of_NeonatalOnset_a"><h4>Complications of Neonatal-Onset and Post-Neonatal-Onset Disease</h4><p><b>Neuropsychological.</b> Typical neuropsychological complications include developmental delay, learning disabilities, intellectual disability [<a class="bk_pop" href="#otc-def.REF.rowe.1986.541">Rowe et al 1986</a>], attention deficit hyperactivity disorder (ADHD), and executive function deficits [<a class="bk_pop" href="#otc-def.REF.gyato.2004.80">Gyato et al 2004</a>, <a class="bk_pop" href="#otc-def.REF.krivitzky.2009.96">Krivitzky et al 2009</a>].</p><ul><li class="half_rhythm"><div>Attention deficit hyperactivity disorder and executive function deficits can greatly affect (school) performance even when intellectual ability is in the normal range [<a class="bk_pop" href="#otc-def.REF.gyato.2004.80">Gyato et al 2004</a>, <a class="bk_pop" href="#otc-def.REF.krivitzky.2009.96">Krivitzky et al 2009</a>].</div></li><li class="half_rhythm"><div>Impulsivity and immaturity can lead to inappropriate behavior and problems in peer relationships especially for preteens and adolescents.</div></li><li class="half_rhythm"><div>In adulthood, problems with <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a> and professional relationships may persist, leading to problems in interpersonal relationships and frequent job changes.</div></li></ul><p>Even asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females were shown to have mild cognitive impairments and executive function deficits on neuropsychological testing [<a class="bk_pop" href="#otc-def.REF.nagata.1991.477">Nagata et al 1991</a>, <a class="bk_pop" href="#otc-def.REF.gyato.2004.80">Gyato et al 2004</a>].</p><p><b>Neurologic.</b> During hyperammonemic coma electroencephalogram (EEG) shows low voltage with slow waves and may include a burst suppression pattern in which the duration of the interburst interval correlates with the height of the ammonia levels [<a class="bk_pop" href="#otc-def.REF.clancy.1991.222">Clancy &#x00026; Chung 1991</a>].</p><p>Seizures are common during hyperammonemic coma and may only be detected on EEG. They do not indicate a poor prognosis. However, persons with urea cycle disorders may also be prone to having seizures independent of hyperammonemic episodes [<a class="bk_pop" href="#otc-def.REF.zecavati.2008">Zecavati et al 2008</a>].</p><p><b>Neuroimaging studies</b> reveal, during a crisis, cerebral edema with small ventricles, flattening of cerebral gyri, and low density of white matter [<a class="bk_pop" href="#otc-def.REF.kendall.1983.28">Kendall et al 1983</a>].</p><p>Neonates who survived after prolonged coma may have ventriculomegaly, diffuse brain atrophy (not affecting the cerebellum), low-density white matter defects, and injury to the bilateral lentiform nuclei and the deep sulci of the insular and perirolandic regions [<a class="bk_pop" href="#otc-def.REF.kendall.1983.28">Kendall et al 1983</a>, <a class="bk_pop" href="#otc-def.REF.yamanouchi.2002.91">Yamanouchi et al 2002</a>, <a class="bk_pop" href="#otc-def.REF.takanashi.2003.390">Takanashi et al 2003</a>, <a class="bk_pop" href="#otc-def.REF.majoie.2004.32">Majoie et al 2004</a>].</p><p>Although metabolic strokes (involving the caudate and putamen and resulting in extrapyramidal syndromes) have been described in OTC deficiency and CPS1 deficiency (see <a href="/books/n/gene/ucd-overview/">Urea Cycle Disorders Overview</a>) [<a class="bk_pop" href="#otc-def.REF.keegan.2003.259">Keegan et al 2003</a>, <a class="bk_pop" href="#otc-def.REF.takanashi.2003.390">Takanashi et al 2003</a>], they are not typical for urea cycle disorders.</p><p>Note: For more information regarding MR spectroscopy research results in OTC deficiency see <a href="/books/NBK154378/bin/otc-def-pathophysiology.pdf">Pathophysiology</a> (pdf).</p><p><b>Neuropathology</b> in those children who died after prolonged coma included cortical atrophy with ventriculomegaly, prominent cortical neuronal loss, and spongiform changes at the gray-white interface and in the basal ganglia and thalamus [<a class="bk_pop" href="#otc-def.REF.dolman.1988.10">Dolman et al 1988</a>].</p><p>Better neurologic outcomes are seen in infants with neonatal-onset disease who were treated soon after the onset of coma.</p><p><b>Gastrointestinal</b></p><ul><li class="half_rhythm"><div>During a hyperammonemic crisis liver enzymes are typically moderately elevated and PT and PTT may be prolonged.</div></li><li class="half_rhythm"><div>Severe elevations of liver enzyme and coagulopathy consistent with acute liver failure are more typically seen in individuals with OTC deficiency after the neonatal period [<a class="bk_pop" href="#otc-def.REF.mustafa.2006.586">Mustafa &#x00026; Clarke 2006</a>].</div></li><li class="half_rhythm"><div>Prolonged PT and PTT as well as mildly increased direct bilirubin are also observed in persons with a urea cycle disorder during long-term follow up when ammonia levels are normal and the individual is asymptomatic.</div></li></ul><p>Liver cell carcinoma has recently been described in a few older individuals (e.g., in a symptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female age 66 years [<a class="bk_pop" href="#otc-def.REF.wilson.2012.263">Wilson et al 2012</a>]), suggesting that OTC deficiency may be associated with an increased risk for liver cancer. However, data are currently insufficient to support such a conclusion.</p></div></div><div id="otc-def.Pathophysiology"><h3>Pathophysiology</h3><p>For more information about the pathophysiology of OTC, click <a href="/books/NBK154378/bin/otc-def-pathophysiology.pdf">here</a>.</p></div><div id="otc-def.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>While the following <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> do in general exist, it is well established that significant medical problems (e.g., neonatal sepsis or other causes of newborn catabolism) can cause a severe, early presentation in an individual with an <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> typically associated with mild disease, making it appear that the pathogenic variant is associated with severe neonatal-onset disease. Likewise, individuals with pathogenic variants associated with mild, late-onset disease (including females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a milder pathogenic variant and skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>) may experience severe life-threatening hyperammonemia at any time in their life when they are exposed to strong environmental stressors.</p><p>In general:</p><ul><li class="half_rhythm"><div>Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that affect residues essential for catalysis, substrate binding, and folding severely impair or completely abolish OTC enzyme activity and result in neonatal-onset disease in <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>].</div></li><li class="half_rhythm"><div>Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, insertions, and deletions that cause frameshift of the <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> and single-nucleotide variants in canonical <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> splice sites result in complete absence of functional OTC and neonatal-onset disease in <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>].</div></li><li class="half_rhythm"><div>Females <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can develop symptoms of OTC deficiency later in life if <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> in their hepatocytes is skewed in favor of the X chromosome with the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#otc-def.REF.mccullough.2000.313">McCullough et al 2000</a>, <a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>].</div></li><li class="half_rhythm"><div>Amino acid substitutions that decrease OTC enzyme activity or stability may result in a post-neonatal-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>] and <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females [<a class="bk_pop" href="#otc-def.REF.pinner.2010.361">Pinner et al 2010</a>].</div></li><li class="half_rhythm"><div>Although one would only expect pathogenic variants that cause severe neonatal-onset disease in <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males to be associated with disease manifestation in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, symptoms of OTC deficency in two females heterozygous for a <a class="def" href="/books/n/gene/glossary/def-item/hypomorphic/">hypomorphic</a> <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> were reported [<a class="bk_pop" href="#otc-def.REF.pinner.2010.361">Pinner et al 2010</a>].</div></li></ul></div><div id="otc-def.Penetrance"><h3>Penetrance</h3><p>Penetrance for OTC deficiency is complete in <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> males.</p><p>The following observations, which may erroneously be interpreted as evidence of incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, are in fact explained by <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> and environmental factors:</p><ul><li class="half_rhythm"><div>Heterozygous females who become symptomatic (the result of skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>)</div></li><li class="half_rhythm"><div>Hemizygous males with the same mild <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, only some of whom develop symptoms (the result of differences in environmental stressors)</div></li></ul></div><div id="otc-def.Prevalence"><h3>Prevalence</h3><p>OTC deficiency is thought to be the most common urea cycle defect (see <a href="/books/n/gene/ucd-overview/">Urea Cycle Disorders Overview</a>).</p><p>Estimated prevalence of OTC deficiency was one in 14,000 live births [<a class="bk_pop" href="#otc-def.REF.brusilow.1996.127">Brusilow &#x00026; Maestri 1996</a>]. However, other surveys of incidence of OTC deficiency in Italy, Finland, and New South Wales, Australia, revealed a lower prevalence of one in 70,000, one in 62,000, and one in 77,000 live births, respectively [<a class="bk_pop" href="#otc-def.REF.dionisivici.2002.321">Dionisi-Vici et al 2002</a>, <a class="bk_pop" href="#otc-def.REF.keskinen.2008.1412">Keskinen et al 2008</a>, <a class="bk_pop" href="#otc-def.REF.balasubramaniam.2010.34">Balasubramaniam et al 2010</a>].</p><p>Given that males and females with partial OTC deficiency may manifest symptoms at any age, prevalence numbers are biased toward the earliest and most severe presentations.</p></div></div><div id="otc-def.Genetically_Related_Allelic_Diso"><h2 id="_otc-def_Genetically_Related_Allelic_Diso_">Genetically Related (Allelic) Disorders</h2><p><b>Contiguous <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions involving <i>OTC</i>.</b> The chromosomal region that includes <i>OTC</i> is a disease-gene-rich region; therefore, individuals with a large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> that includes <i>OTC</i> may have two life-threatening diseases &#x02013; <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> <a href="/books/n/gene/cgd/">chronic granulomatous disease</a> and OTC deficiency &#x02013; as well as additional diseases with significant morbidity: <a href="/books/n/gene/rp-overview/">retinitis pigmentosa 3</a>, <a href="/books/n/gene/mcleod/">McLeod neuroacanthocytosis syndrome</a>, <a href="/books/n/gene/dbmd/">Duchenne muscular dystrophy</a>, and oculo-facio-cardio-dental syndrome (OMIM <a href="http://omim.org/entry/300166" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">300166</a>) [<a class="bk_pop" href="#otc-def.REF.deardorff.2008.498">Deardorff et al 2008</a>, <a class="bk_pop" href="#otc-def.REF.di_stefano.2015.203">Di Stefano et al 2015</a>]. The breakpoints of deletions and rearrangements differ in each individual and thus do NOT lead to a recurrent <a class="def" href="/books/n/gene/glossary/def-item/microdeletion-syndrome/">microdeletion syndrome</a>.</p></div><div id="otc-def.Differential_Diagnosis"><h2 id="_otc-def_Differential_Diagnosis_">Differential Diagnosis</h2><p>Neonatal-onset urea cycle disorders (UCDs) &#x02013; N-acetylglutamate synthase (NAGS) deficiency, severe carbamyl phosphate synthetase I (CPSI) deficiency, argininosuccinate synthetase (ASS) deficiency (<a href="/books/n/gene/ctlm/">citrullinemia type I</a>), and <a href="/books/n/gene/args-aciduria/">argininosuccinate lyase (ASL) deficiency</a> (argininosuccinic aciduria [ASA]) &#x02013; show the same clinical symptoms at presentation as severe OTC deficiency. See <a href="/books/n/gene/ucd-overview/">Urea Cycle Disorders Overview</a>.</p><p>Respiratory alkalosis is a typical finding in UCD [<a class="bk_pop" href="#otc-def.REF.maestri.1999.268">Maestri et al 1999</a>] and its presence clearly distinguishes a UCD from an organic acidemia presenting with hyperammonemia and ketoacidosis. However, when a child who has been in a coma for days becomes terminally ill, acidosis rather than respiratory alkalosis may be present.</p></div><div id="otc-def.Management"><h2 id="_otc-def_Management_">Management</h2><div id="otc-def.Evaluations_Following_Initial_Di"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with ornithine transcarbamylase (OTC) deficiency, the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Plasma ammonia concentration</div></li><li class="half_rhythm"><div>Plasma amino acid analysis</div></li><li class="half_rhythm"><div>Laboratory values that reflect nutritional status (e.g., vitamin D level, ferritin, pre-albumin)</div></li><li class="half_rhythm"><div>Liver function tests (liver enzymes, bilirubin, albumin)</div></li><li class="half_rhythm"><div>PT/PTT and fibrinogen</div></li><li class="half_rhythm"><div>Developmental/neuropsychological/psychological evaluation</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="otc-def.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment is best provided by a clinical geneticist and a nutritionist experienced in the treatment of metabolic disease.</p><div id="otc-def.Care_of_Hyperammonemic_Coma"><h4>Care of Hyperammonemic Coma</h4><p>Care should be provided by a team coordinated by a metabolic specialist in a tertiary care center experienced in the management of individuals with OTC deficiency. In the <b>acute phase</b>, the mainstays of treatment are the following.</p><p><b>Rapid lowering of the plasma ammonia</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Level should be 200 &#x003bc;mol/L or lower even if a diagnosis has not yet been established because of the severely toxic effect of an elevated ammonia level on the brain.</div></li><li class="half_rhythm"><div class="half_rhythm">The fastest method for lowering the ammonia level is hemodialysis [<a class="bk_pop" href="#otc-def.REF.tuchman.1992.836">Tuchman 1992</a>, <a class="bk_pop" href="#otc-def.REF.mcbryde.2004.536">McBryde et al 2004</a>]:</div><ul><li class="half_rhythm"><div>A neonate should not be hemodialysed longer than four hours and should then be switched to hemofiltration for stabilization to prevent a rebound of the ammonia level.</div></li><li class="half_rhythm"><div>An older individual can be dialysed longer and should also be switched to hemofiltration for stabilization.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Depending on the height of the ammonia level (&#x02264;1500 &#x003bc;mol/L), one can also start with high flow hemofiltration methods to achieve a similarly speedy reduction of the ammonia level and then switch to regular hemofiltration for stabilization to prevent a rebound of the ammonia level.</div><div class="half_rhythm">Note: Peritoneal dialysis is ineffective for management of acute hyperammonemia and is not recommended.</div></li></ul><p><b>Ammonia scavenger therapy</b></p><ul><li class="half_rhythm"><div>Treatment allows an alternative pathway for the excretion of excess nitrogen (see <a class="figpopup" href="/books/NBK154378/table/otc-def.T.intravenous_iv_ammonia_scaveng/?report=objectonly" target="object" rid-figpopup="figotcdefTintravenousivammoniascaveng" rid-ob="figobotcdefTintravenousivammoniascaveng">Table 2</a>).</div></li><li class="half_rhythm"><div>Nitrogen scavenger therapy is available as an intravenous infusion of a mixture of sodium phenylacetate and sodium benzoate for acute management and as an oral preparation of phenylbutyrate or sodium benzoate for long-term maintenance therapy.</div></li><li class="half_rhythm"><div>Citrulline is supplemented at 170 mg/kg/day or 3.8g/m2/day (enterally).</div></li></ul><div id="otc-def.T.intravenous_iv_ammonia_scaveng" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Intravenous (IV) Ammonia Scavenger Therapy Protocol Used in OTC Deficiency and Carbamyl Phosphate Synthetase I (CPSI) Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154378/table/otc-def.T.intravenous_iv_ammonia_scaveng/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__otc-def.T.intravenous_iv_ammonia_scaveng_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_1" style="text-align:left;vertical-align:middle;">Patient Weight</th><th id="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Components of Infusion Solution</th><th id="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Loading&#x000a0;<sup>1</sup> and Maintenance Dose&#x000a0;<sup>2,&#x000a0;3</sup></th></tr><tr><th headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_2" id="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sodium phenylacetate &#x00026; sodium benzoate&#x000a0;<sup>4</sup></th><th headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_2" id="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Arginine HCl injection, 10%</th><th headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3" id="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sodium phenylacetate</th><th headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3" id="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sodium benzoate</th><th headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3" id="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Arginine HCl&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>&#x0003c;25 kg</b></td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_2 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Undiluted: 2.5 mL (contains 250 mg of each)<br />Dilute 1:10&#x000a0;<sup>4</sup></td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_2 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.0 mL at 100 mg/mL</td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">250 mg/kg</td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">250 mg/kg</td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">200 mg/kg</td></tr><tr><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>&#x02265;25 kg</b></td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_2 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Undiluted: 55 mL (contains 5,500 mg of each)<br />Dilute 1:10&#x000a0;<sup>4</sup></td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_2 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40 mL at 100 mg/mL</td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5,500 mg/m<sup>2</sup></td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5,500 mg/m<sup>2</sup></td><td headers="hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_1_3 hd_h_otc-def.T.intravenous_iv_ammonia_scaveng_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4,000 mg/m<sup>2</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#otc-def.REF.batshaw.2001.s46">Batshaw et al [2001]</a></p></div></dd><dt>1. </dt><dd><div id="otc-def.TF.2.1"><p class="no_margin">Loading dose given over 90 to 120 minutes</p></div></dd><dt>2. </dt><dd><div id="otc-def.TF.2.2"><p class="no_margin">Maintenance dose given over 24 hours</p></div></dd><dt>3. </dt><dd><div id="otc-def.TF.2.3"><p class="no_margin">If an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has symptomatic hyperammonemia and has not received a full dose of ammonia scavenger in the previous 12 hours, the affected person should first receive an IV bolus directly followed by maintenance infusion.</p></div></dd><dt>4. </dt><dd><div id="otc-def.TF.2.4"><p class="no_margin">Sodium phenylacetate/sodium benzoate must be diluted with sterile 10% dextrose before administration. The typical dilution is 1:10.</p></div></dd><dt>5. </dt><dd><div id="otc-def.TF.2.5"><p class="no_margin">Arginine infusion not to exceed 150mg/kg/h</p></div></dd></dl></div></div></div><p><b>Reversal of catabolism</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Provide calories from glucose and fat, and resume protein intake (in the form of natural protein and an essential amino acid mix) no later than 24 hours after protein intake was discontinued</div><div class="half_rhythm">Note: Persons on hemodialysis or hemofiltration in particular need adequate nutrition to overcome catabolism because nutrients are removed by these procedures. Discontinuation of protein intake should not exceed 24 hours because deficiency of essential amino acids results in muscle breakdown and uncontrolled nitrogen release. Daily quantitative plasma amino acid analysis should guide nutritional therapy, the goal of which is to keep essential amino acid levels in the normal range.</div></li><li class="half_rhythm"><div class="half_rhythm">Use of a high glucose infusion rate supported by continuous insulin infusion to maintain high set point normoglycemia (140 mg/dL) as needed. For a newborn in crisis the goal is to deliver at least 100 kcal/kg/day, mostly from glucose and fat.</div></li></ul><p><b>Reducing the risk of neurologic damage</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Affected individuals who are intubated and sedated may not show clinical signs of seizures, which are prevalent in acute hyperammonemia. EEG surveillance is thus highly recommended to allow electroencephalographic detection and subsequent treatment of seizures.</div><div class="half_rhythm">Note: Phenobarbital is removed by dialysis and valproic acid is contraindicated in urea cycle disorders.</div></li><li class="half_rhythm"><div class="half_rhythm">The use of hypothermia for neuroprotection in hyperammonemia has long been proposed [<a class="bk_pop" href="#otc-def.REF.vaquero.2007.528">Vaquero &#x00026; Butterworth 2007</a>] but has yet to be proven efficacious. A pilot study showed feasibility and safety (see <a href="#otc-def.Therapies_Under_Investigation">Therapies Under Investigation</a>).</div></li><li class="half_rhythm"><div class="half_rhythm">No other interventions (besides lowering the ammonia level) have proven efficacy for neuroprotection in hyperammonemic coma due to a urea cycle disorder or other conditions.</div></li></ul></div><div id="otc-def.LongTerm_Treatment"><h4>Long-Term Treatment</h4><p>Long-term treatment (including restriction of protein intake, use of nitrogen scavengers, and in some cases liver transplantation) is aimed at promoting growth and development and preventing hyperammonemic episodes.</p><p><b>Protein intake</b>
<b>should be restricted</b> to the required dietary allowance (RDA) for protein or the minimum amount necessary to allow growth and prevent catabolism depending on the severity of the disease. Use of an essential amino acid mixture is generally necessary to maintain normal essential amino acid levels in those on significant protein restriction, even persons with partial OTC deficiency. The diet should also provide vitamins, minerals, and trace elements, either in a calorie-rich, protein-free formula or in the form of supplements.</p><p>Although protein restriction is the mainstay of therapy, when protein intake is too low, catabolism can cause chronic hyperammonemia just as high protein intake does. Careful monitoring of plasma amino acid concentrations is necessary to detect essential amino acid deficiencies. High glutamine concentrations are interpreted as evidence of poor metabolic control and chronic hyperammonemia.</p><p><b>Nitrogen scavengers</b> provide alternative routes for nitrogen disposal and allow more protein intake [<a class="bk_pop" href="#otc-def.REF.batshaw.2001.s46">Batshaw et al 2001</a>, <a class="bk_pop" href="#otc-def.REF.berry.2001.s56">Berry &#x00026; Steiner 2001</a>].</p><p>Although it removes only half as much nitrogen as phenylbutyrate, oral sodium benzoate is the ammonia scavenger of choice in European countries and Australia rather than phenylbutyrate because it is felt to have fewer side effects.</p><p>Phenylbutyrate causes menstrual dysfunction and body odor, and appears to deplete branched chain amino acids; sodium benzoate causes hypokalemia due to increased renal losses of potassium [<a class="bk_pop" href="#otc-def.REF.scaglia.2004.s79">Scaglia et al 2004</a>, <a class="bk_pop" href="#otc-def.REF.h_berle.2012.32">H&#x000e4;berle et al 2012</a>].</p><p>Recommendations for ammonia scavenger therapy:</p><ul><li class="half_rhythm"><div class="half_rhythm">Long-term ammonia scavenger treatment may consist of 450-600 mg/kg/day of sodium phenylbutyrate and 170 mg/kg/day of L-citrulline in children &#x0003c;25 kg, and 9.9-13.0 g/m<sup>2</sup>/day of sodium phenylbutyrate and 3.8 g/m<sup>2</sup>/day of L-citrulline in individuals weighing &#x02265;25 kg. Treatment should be accompanied by an appropriate low-protein diet [<a class="bk_pop" href="#otc-def.REF.batshaw.2001.s46">Batshaw et al 2001</a>].</div><div class="half_rhythm">Note: (1) Citrulline offers the advantage over arginine of incorporating aspartate into the pathway thus pulling one additional nitrogen molecule into the urea cycle. (2) Sodium benzoate is being used instead of sodium phenylbutyrate in conjunction with L-citrulline. The recommended dose is &#x02264;250 mg/kg/d in children &#x0003c;25 kg and a maximum of 12 g/d [<a class="bk_pop" href="#otc-def.REF.h_berle.2012.32">H&#x000e4;berle et al 2012</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Glycerol phenylbutyrate, which is significantly more palatable than sodium phenylbutyrate, is another treatment option. It has the same mechanism of action as sodium phenylbutyrate.</div></li></ul><p><b>Liver transplantation.</b> No matter how mild OTC deficiency appears to be, stressors can at any age precipitate a hyperammonemic crisis that becomes life threatening. The fear of such an event, along with the restrictions on daily living imposed by the dietary therapy, prompt many families to consider liver transplantation even if the disease has been manageable up to that point with diet and medication.</p><ul><li class="half_rhythm"><div>In severe, neonatal-onset urea cycle disorders, liver transplantation remains the most effective means of preventing further hyperammonemic crises and neurodevelopmental deterioration [<a class="bk_pop" href="#otc-def.REF.leonard.2004.s74">Leonard &#x00026; McKiernan 2004</a>]. It is typically performed by age six months.</div></li><li class="half_rhythm"><div>Females and males with partial OTC deficiency can, after diagnosis, be maintained on a low-protein diet and oral ammonia scavenger treatment for life; the need for liver transplant depends on the individual and is typically considered when an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual is unstable and has frequent hyperammonemic episodes.</div></li><li class="half_rhythm"><div>Living related donor livers are often considered for partial liver transplantation (LT) in individuals with a urea cycle disorder. The suitability of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> mother as a donor has been discussed [<a class="bk_pop" href="#otc-def.REF.wong.2012.525">Wong 2012</a>]. According to <a class="bk_pop" href="#otc-def.REF.wakiya.2012.404">Wakiya et al [2012]</a>, enzyme activity measurement in a liver biopsy sample is useful in determining the suitability of a heterozygous mother as a donor. However, this approach is problematic for several reasons:</div><ul><li class="half_rhythm"><div>A liver biopsy sample may not adequately represent the enzyme activity in the liver of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female. It can thus not be known whether a transplanted lobe contains enough enzyme activity to prevent symptoms in the recipient.</div></li><li class="half_rhythm"><div>After partial hepatectomy the liver of the donor mother will regenerate. Since the <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> pattern in the regenerated liver in the donor cannot be predicted, it is also impossible to predict whether the overall enzyme activity in the donor mother will remain adequate to prevent symptoms in her.</div></li><li class="half_rhythm"><div>Likewise, the lobe that is transplanted into the recipient child will undergo changes after transplantation; thus, the enzyme activity in the donated lobe cannot be accurately determined at the time of transplantation, since additional post-transplantation changes could make the final enzyme activity in the recipient even more unpredictable.</div></li></ul></li></ul><p>Note: The efficacy of hepatocyte transfer for providing sufficient enzyme activity to bridge the time to liver transplantation in unstable individuals with neonatal-onset disease is currently under investigation (see <a href="#otc-def.Therapies_Under_Investigation">Therapies Under Investigation</a>).</p><p><b>Attention deficit/hyperactivity disorder (ADHD).</b> Instruction in small classroom settings to minimize distraction and extra support to manage executive function deficits are often required and necessary to maximize success in school.</p><p>Monotherapy or combination therapy with non-stimulant or stimulant medication is often necessary for the treatment of ADHD (at least during times of learning) [<a class="bk_pop" href="#otc-def.REF.gyato.2004.80">Gyato et al 2004</a>, <a class="bk_pop" href="#otc-def.REF.krivitzky.2009.96">Krivitzky et al 2009</a>]. However, these medications negatively affect appetite and their use warrants even closer monitoring of intake and body weight to avoid a catabolic state that could lead to hyperammonemia.</p><p><b>Seizure disorders.</b> Valproic acid is contraindicated for treatment of seizures in urea cycle disorders because it can cause a hyperammonemic crisis.</p><p><b>Learning disability/intellectual disability.</b> Brain damage from an initial hyperammonemic coma, frequent hyperammonemic episodes with moderate to severe hyperammonemia, and chronic hyperammonemia can lead to learning disabilities and intellectual disability. Appropriate support services are necessary to optimize intellectual outcome in these individuals.</p><p>Also see <a href="/books/n/gene/ucd-overview/">Urea Cycle Disorders Overview</a>.</p></div></div><div id="otc-def.Prevention_of_Primary_Manifestat"><h3>Prevention of Primary Manifestations</h3><p>In neonatal-onset OTC deficiency diagnosed prenatally, prospective intravenous (IV) treatment with ammonia scavengers within a few hours of birth (before the ammonia level rises) can prevent a hyperammonemic crisis and coma.</p><p>Later on, prevention of hyperammonemic episodes is focused on restriction of dietary protein through low-protein diet and administration of oral nitrogen scavenging drugs balanced with supplementation of essential amino acids (see <a href="#otc-def.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p></div><div id="otc-def.Prevention_of_Secondary_Complica"><h3>Prevention of Secondary Complications</h3><p>The following are recommended:</p><ul><li class="half_rhythm"><div>Avoid overrestriction of protein/amino acids, a common cause of hyperammonemia and poor growth. Gastrostomy tube feedings help avoid malnutrition in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who self-restrict protein intake and object to the taste of the essential amino acid formulas used for the treatment of urea cycle disorders.</div></li><li class="half_rhythm"><div>Minimize risk of respiratory and gastrointestinal illnesses through hand hygiene.</div></li><li class="half_rhythm"><div>Give immunizations on the usual schedule, including annual flu vaccine.</div></li><li class="half_rhythm"><div>Provide multivitamin and vitamin D supplementation.</div></li><li class="half_rhythm"><div>Use antipyretics appropriately. Note: Ibuprofen is preferred in the home setting over acetaminophen because of the potential liver toxicity of acetaminophen.</div></li></ul><p>See also <a href="#otc-def.Therapies_Under_Investigation">Therapies Under Investigation</a> regarding the use of hypothermia as neuroprotective therapy to prevent intellectual disability, a complication of hyperammonemia.</p></div><div id="otc-def.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>At the start of therapy, measure <b>plasma ammonia</b> concentration at least every two weeks (or more often depending on the stability of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual), then slowly extend to every month, every two months, every three months, and every four months, as possible.</div></li><li class="half_rhythm"><div>At the start of therapy, perform <b>plasma amino acid (PAA)</b> analysis at least every two weeks (or more often depending on the stability of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual), then slowly extend to every month, every two months, every three months, and every four months.</div></li><li class="half_rhythm"><div>Perform <b>liver function tests</b> depending on symptoms every three to six months or more often if they have been previously elevated.</div></li><li class="half_rhythm"><div>Perform <b>neuropsychological testing</b> at the time that significant developmental milestones are expected to be achieved (e.g., at 6-9 months, 18 months, 3 years)</div></li></ul></div><div id="otc-def.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Valproate</div></li><li class="half_rhythm"><div class="half_rhythm">Haloperidol</div></li><li class="half_rhythm"><div class="half_rhythm">Fasting</div></li><li class="half_rhythm"><div class="half_rhythm">Stress, especially physical stress; potentially also psychological stress</div></li><li class="half_rhythm"><div class="half_rhythm">Systemic corticosteroids because they cause catabolism, which can trigger a hyperammonemic crisis</div><div class="half_rhythm">Note: If systemic corticosteroids need to be administered as a life-saving therapy (e.g., during a severe asthma attack or an anaphylactic reaction), a metabolic specialist should be consulted; at the same time, preemptive measures (e.g., increased calorie intake) should be instituted to prevent catabolism.</div></li></ul></div><div id="otc-def.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives (both male and female) of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from initiation of treatment and/or preventive measures.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known;</div><ul><li class="half_rhythm"><div>If prenatal testing has not been performed, it is appropriate to perform biochemical (plasma amino acid analysis, ammonia level) and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> on at-risk newborns (males and females) as soon after birth as possible to clarify their disease status so that the appropriate treatment or surveillance of those with the family-specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can be promptly established before the child experiences a metabolic crisis.</div></li></ul></li><li class="half_rhythm"><div>Biochemical analysis (plasma amino acid analysis, ammonia level), an allopurinol challenge test (in older individuals), and/or OTC enzyme activity measurement in liver (males only) if the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known.</div></li></ul><p>In general for children with neonatal-onset disease, such testing cannot be performed rapidly enough to prevent a metabolic crisis. Therefore, preventive measures at birth should be instituted until such a time as the diagnosis can be ruled out (see the description of prospective treatment in <a href="#otc-def.Prevention_of_Primary_Manifestat">Prevention of Primary Manifestations</a>).</p><p>See <a href="#otc-def.Related_Genetic_Counseling_Issue">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="otc-def.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Heterozygous females are at risk of becoming catabolic during pregnancy and (especially) post partum [<a class="bk_pop" href="#otc-def.REF.redonnetvernhet.2000.1008">Redonnet-Vernhet et al 2000</a>, <a class="bk_pop" href="#otc-def.REF.mendezfigueroa.2010.775">Mendez-Figueroa et al 2010</a>, <a class="bk_pop" href="#otc-def.REF.celik.2011.1052">Celik et al 2011</a>, <a class="bk_pop" href="#otc-def.REF.lipskind.2011.682">Lipskind et al 2011</a>, <a class="bk_pop" href="#otc-def.REF.ituk.2012.90">Ituk et al 2012</a>].</p><ul><li class="half_rhythm"><div>A symptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female needs to be treated throughout pregnancy according to her pre-pregnancy protocol with adaptation for her needs during pregnancy. In the peripartum and immediate postpartum periods proactive measures to prevent catabolism include, for example, administration of a 10% dextrose solution with appropriate electrolytes at 1.5 times maintenance and addition of intralipids as needed to meet caloric requirements during these periods.</div></li><li class="half_rhythm"><div>In an asymptomatic female known to be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, precautions should be taken in the peripartum and postpartum period to prevent catabolism; in addition, measurement of ammonia levels and administration of dextrose should be considered as heterozygous females have become symptomatic for the first time in the peripartum period.</div></li></ul></div><div id="otc-def.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>The use of <b>hypothermia for neuroprotection</b> in hyperammonemia has long been proposed [<a class="bk_pop" href="#otc-def.REF.vaquero.2007.528">Vaquero &#x00026; Butterworth 2007</a>]. Two case reports were published about its use in UCD [<a class="bk_pop" href="#otc-def.REF.whitelaw.2001.36">Whitelaw et al 2001</a>, <a class="bk_pop" href="#otc-def.REF.vargha.2012.60">Vargha et al 2012</a>].</p><p>Whole-body therapeutic hypothermia (TH) may decrease ammonia production through an overall slowing of metabolism. Decreased ammonia production was indicated in acute liver failure studies by lower arterial ammonia levels with cooling. The success of hemodialysis in lowering the ammonia level depends on whether the amount of ammonia removed by dialysis exceeds the amount of ammonia produced. If TH reduces ammonia production, dialysis will be more effective. In addition to its direct effect on ammonia metabolism TH may have a neuroprotective effect, at least in part due to reduced brain uptake of ammonia, reduced brain glutamine production, normal osmolyte levels, reduced intracranial pressure and cerebral blood flow, and improved cerebral perfusion [<a class="bk_pop" href="#otc-def.REF.jalan.1999.1164">Jalan et al 1999</a>, <a class="bk_pop" href="#otc-def.REF.jalan.2004.1338">Jalan et al 2004</a>].</p><p>Results of a pilot study assessing the feasibility and safety of whole-body therapeutic hypothermia during neonatal hyperammonemic coma have been published [<a href="https://clinicaltrials.gov/ct2/show/NCT01624311?term=lichter-konecki&#x00026;rank=1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>, <a class="bk_pop" href="#otc-def.REF.lichterkonecki.2013.354">Lichter-Konecki et al 2013</a>]. While the study was not able to determine if the treatment was efficacious, the authors concluded that it was feasible and could be conducted safely.</p><p>The efficacy of <b>hepatocyte transfer</b> for providing sufficient enzyme activity is under investigation (see <a href="https://clinicaltrials.gov/ct2/show/NCT01345578?term=urea+cycle&#x00026;rank=39" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a>).</p><p>In September 2009 a meeting in London assessed the "state of the art" of hepatocyte transplantation and limits to its success; according to <a class="bk_pop" href="#otc-def.REF.puppi.2012.1">Puppi et al [2012]</a> the participating experts agreed that, "to obtain sufficient levels of repopulation of the liver with donor cells in patients with metabolic liver disease, some form of liver preconditioning would likely be required to enhance the engraftment and/or proliferation of donor cells. It was reported that clinical protocols for preconditioning by hepatic irradiation, portal vein embolization, and surgical resection had been developed."</p><p>Use of <b>human induced pluripotent stem (iPS) cells</b> is under consideration. The principal concept is the use of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's somatic cells to generate pluripotent stem cells that are then induced to become hepatocytes. Gene therapy could be performed on those hepatocytes in vitro, and the &#x02018;corrected' hepatocytes could then be used for liver regeneration in the same person without the need for immune suppression [<a class="bk_pop" href="#otc-def.REF.sotogutierrez.2011.708">Soto-Gutierrez et al 2011</a>].</p><p><b>Current <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> approach.</b> An adeno-associated virus (AAV) vector construct harboring the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> has been developed; its efficient delivery to the liver of animal models has been accomplished [<a class="bk_pop" href="#otc-def.REF.wang.2010.118">Wang et al 2010</a>, <a class="bk_pop" href="#otc-def.REF.wang.2012a.203">Wang et al 2012a</a>, <a class="bk_pop" href="#otc-def.REF.wang.2012b.404">Wang et al 2012b</a>]. However, most recent efforts have focused on AAV-mediated gene correction using the CRISPR-Cas9 system [<a class="bk_pop" href="#otc-def.REF.yang.2016.334">Yang et al 2016</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="otc-def.Genetic_Counseling"><h2 id="_otc-def_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="otc-def.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Ornithine transcarbamylase (OTC) deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="otc-def.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div class="half_rhythm">In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>). Note: If a woman has more than one affected child and no other affected relatives and if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Germline mosaicism has been reported in OTC deficiency [<a class="bk_pop" href="#otc-def.REF.bowling.1999.452">Bowling et al 1999</a>]; however, because the frequency is not known the general 3%-4% <a class="def" href="/books/n/gene/glossary/def-item/background-risk/">background risk</a> of germline mosaicism should be used.</div></li><li class="half_rhythm"><div class="half_rhythm">If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) or the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a heterozygote (carrier).</div><div class="half_rhythm">Note: Generally, Haldane's rule (i.e., 2/3 of cases are inherited and 1/3 are <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants) is used for <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> lethal diseases. This rule assumes that the mutation rate is equal between male and female germ cells. A study by <a class="bk_pop" href="#otc-def.REF.tuchman.1995.67">Tuchman et al [1995]</a> concluded that the mutation rate was significantly lower in male germ cells than in female germ cells and described a spontaneous mutation rate of 7% when the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> was male, versus 80% if the proband was female. <a class="bk_pop" href="#otc-def.REF.r_egger.2014.21">R&#x000fc;egger et al [2014]</a> reported a spontaneous mutation rate of 26% when the proband was male and of 67% when the proband was female.</div></li></ul><p><b>Parents of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>An <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> female may have inherited the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from either her mother or her father, or the pathogenic variant may be <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>.</div></li><li class="half_rhythm"><div>Detailed evaluation of the parents and review of the extended family history may help distinguish probands with a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from those with an inherited pathogenic variant. Molecular genetic testing of the mother (and subsequently the father) can determine if the pathogenic variant was inherited.</div></li></ul><p><b>Sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant may or may not develop clinical findings related to the disorder (see <b>Offspring of a female proband</b>).</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Sibs of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the parents:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant may or may not develop clinical findings related to the disorder (see <b>Offspring of a female proband</b>).</div></li><li class="half_rhythm"><div>If the father of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, he will transmit it to all of his daughters and none of his sons.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Males with OTC deficiency used to die before reproductive age or be too debilitated to reproduce. However, prospective treatment as soon as the child is born and improved rescue therapy followed by liver transplant now allows such males to reach reproductive age and reproduce.</div></li><li class="half_rhythm"><div>Males with late-onset, moderate-to-mild partial OTC deficiency can reproduce. Affected males transmit the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</div><ul><li class="half_rhythm"><div>All of their daughters, who will be heterozygotes and may or may not develop clinical symptoms related to the disorder;</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul></li></ul><p><b>Offspring of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b>. Women with an <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a 50% chance of transmitting the pathogenic variant to each child:</p><ul><li class="half_rhythm"><div>Males who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>Females who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be heterozygotes and may or may not develop clinical findings related to the disorder (see <b>Other family members</b>).</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p><p>Note: Molecular genetic testing may be able to identify the family member in whom a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> arose, information that could help determine genetic risk status of the extended family.</p></div><div id="otc-def.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p>Note: (1) The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can range from asymptomatic to significant symptoms with recurrent hyperammonemia and neurologic compromise (see Clinical Description, <a href="#otc-def.Heterozygous_Females">Heterozygous Females</a>). (2) Identification of female heterozygotes requires either (a) prior identification of the <i>OTC</i> pathogenic variant in the family or, (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and if no pathogenic variant is identified, by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p><p>If the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family cannot be identified:</p><ul><li class="half_rhythm"><div class="half_rhythm">Options that may help clarify the genetic status of female family members include an allopurinol challenge (see <a href="#otc-def.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</div></li><li class="half_rhythm"><div class="half_rhythm">Linkage analysis may be helpful in determining the genetic status of at-risk female relatives in informative families.</div><div class="half_rhythm">Note: When linkage analysis is performed for clinical use, the <a class="def" href="/books/n/gene/glossary/def-item/recombination/">recombination</a> rate and mutation rate of the markers used needs to be known. Also, the availability of linkage analysis varies.</div></li></ul></div><div id="otc-def.Related_Genetic_Counseling_Issue"><h3>Related Genetic Counseling Issues</h3><p>See <a href="#otc-def.Evaluation_of_Relatives_at_Risk">Evaluating Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, have an <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, or are at risk of having an <i>OTC</i> pathogenic variant.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="otc-def.Prenatal_Testing_and_Preimplanta"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for OTC deficiency are possible.</p><p>Linkage analysis may be an option if the <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be identified.</p><p>Because males with a neonatal presentation are more severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, knowing the fetal sex may provide additional information helpful to families and health care providers in the newborn period.</p><ul><li class="half_rhythm"><div>In a family with a history of neonatal-onset disease, it is likely (but not certain) that subsequently <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males will have a similar presentation.</div></li><li class="half_rhythm"><div>Because of the unpredictability of <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>, it is not possible to predict the presentation in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females (see Clinical Characteristics, <a href="#otc-def.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</div></li></ul></div></div><div id="otc-def.Resources"><h2 id="_otc-def_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Connecting Families - Urea Cycle Disorders (UCD) Foundation</b></div><div>Community and Resources for Families</div><div>39252 Winchester Road, #107-135</div><div>Murrieta CA 92563</div><div><b>Phone:</b> 918-490-3055</div><div><a href="http://www.ucdfamily.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ucdfamily.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=ornithinetranscarbamylasedeficiency" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ornithine transcarbamylase deficiency</a></div></li><li class="half_rhythm"><div><b>National Urea Cycle Disorders Foundation</b></div><div>75 South Grand Avenue</div><div>Pasadena CA 91105</div><div><b>Phone:</b> 800-386-8233 (toll-free); 626-578-0833</div><div><b>Fax:</b> 626-578-0823</div><div><b>Email:</b> info@nucdf.org</div><div><a href="http://www.nucdf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nucdf.org</a></div></li><li class="half_rhythm"><div><b>National Organization for Rare Disorders (NORD)</b></div><div>RareCareSM</div><div><b>Phone:</b> 800-999-6673</div><div><a href="https://rarediseases.org/for-patients-and-families/help-access-medications/patient-assistance-programs-2/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Assistance Programs</a></div></li><li class="half_rhythm"><div><b>European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD)</b></div><div><a href="https://www.e-imd.org/event/european-registry-and-network-intoxication-type-metabolic-diseases" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.e-imd.org/en/index.phtml</a></div></li><li class="half_rhythm"><div><b>Urea Cycle Disorder International Patient Registry</b></div><div><b>Phone:</b> 626-578-0833</div><div><b>Fax:</b> 626-578-0823</div><div><b>Email:</b> coordinator@ucdparegistry.org</div><div><a href="https://ucdparegistry.patientcrossroads.org/index.php?option=com_content&#x00026;view=article&#x00026;id=412&#x00026;Itemid=484" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ucdregistry.org</a></div></li><li class="half_rhythm"><div><b>Urea Cycle Disorders Consortium Registry</b></div><div>Children's National Medical Center</div><div><b>Phone:</b> 202-306-6489</div><div><b>Email:</b> jseminar@childrensnational.org</div><div><a href="https://www.rarediseasesnetwork.org/cms/ucdc/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rarediseasesnetwork.org/cms/ucdc/</a></div></li></ul></div><div id="otc-def.Molecular_Genetics"><h2 id="_otc-def_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="otc-def.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Ornithine Transcarbamylase Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154378/table/otc-def.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__otc-def.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_otc-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_otc-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_otc-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_otc-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_otc-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_otc-def.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_otc-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5009" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>OTC</i></a></td><td headers="hd_b_otc-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5009" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xp11<wbr style="display:inline-block"></wbr>​.4</a></td><td headers="hd_b_otc-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P00480" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ornithine carbamoyltransferase, mitochondrial</a></td><td headers="hd_b_otc-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.lovd.nl/OTC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ornithine CarbamoylTransferase (OTC) @ LOVD</a></td><td headers="hd_b_otc-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=OTC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OTC</a></td><td headers="hd_b_otc-def.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=OTC[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OTC</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="otc-def.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="otc-def.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Ornithine Transcarbamylase Deficiency (<a href="/omim/300461,311250" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154378/table/otc-def.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__otc-def.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300461" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300461</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ORNITHINE CARBAMOYLTRANSFERASE; OTC</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/311250" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">311250</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO</td></tr></tbody></table></div></div><div id="otc-def.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>OTC deficiency results from pathogenic variants in <i>OTC</i> that reduce its expression, lead to abnormally spliced <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>, or result in an enzyme with reduced or absent activity.</p><p><b>Gene structure.</b> The <i>OTC</i> reference sequence (<a href="/nuccore/NM_000531.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000531.5</a>) has ten exons and nine introns that span 73 kb. The regulatory regions of human <i>OTC</i> include a 793-bp promoter located immediately upstream of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 and a 465-bp enhancer located approximately 9 kb (9,177 to 9,641 bp) upstream of the <i>OTC</i> translation initiation codon [<a class="bk_pop" href="#otc-def.REF.luksan.2010.e1294">Luksan et al 2010</a>]. Transcription of human <i>OTC</i> initiates at three sites located 95, 119, and 169 bp upstream of the translation initiation codon [<a class="bk_pop" href="#otc-def.REF.luksan.2010.e1294">Luksan et al 2010</a>]. Human <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> is approximately 1,500 nucleotides long with a 1,062-nucleotide <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> [<a class="bk_pop" href="#otc-def.REF.horwich.1984.1068">Horwich et al 1984</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK154378/#otc-def.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Common <i>OTC</i> polymorphisms include benign variants in the promoter [<a class="bk_pop" href="#otc-def.REF.azevedo.2003.152">Azevedo et al 2003</a>], the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>, and the vicinity of splice sites [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a> ]. These variants are presumed to be neutral in their effect on <i>OTC</i> expression and the function of the OTC enzyme.</p><p><b>Pathogenic variants.</b> More than 400 pathogenic <i>OTC</i> variants have been described in the literature [<a class="bk_pop" href="#otc-def.REF.bailly.2015.e146">Bailly et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.choi.2015.501">Choi et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.gao.2015.474.e1">Gao et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.mohamed.2015.1229">Mohamed et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.prasun.2015.782">Prasun et al 2015</a>].</p><p>Additionally, 972 <i>OTC</i> variants, pathogenic and non-pathogenic, have been collected and curated in the <a href="http://chromium.lovd.nl/LOVD2/home.php?select_db=OTC" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Leiden Open Variation Database</a>.</p><p>Types of pathogenic variants:</p><ul><li class="half_rhythm"><div>About 17% of reported pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, insertions, or deletions in the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> that result in truncated protein and complete absence of functional OTC [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.choi.2015.501">Choi et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.gao.2015.474.e1">Gao et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.prasun.2015.782">Prasun et al 2015</a>]. An additional 2% of reported pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions and insertions that disrupt structure of the OTC enzyme although they do not affect the reading frame of the <i>OTC</i> coding sequence [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>].</div></li><li class="half_rhythm"><div>About 55% of reported pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants [<a class="bk_pop" href="#otc-def.REF.bailly.2015.e146">Bailly et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.choi.2015.501">Choi et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.gao.2015.474.e1">Gao et al 2015</a>]. Although deleterious amino acid substitutions have been found throughout the OTC protein <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>, exons 1 and 7 appear to have fewer deleterious missense variants than other exons. This is possibly because they encode the mitochondrial targeting peptide [<a class="bk_pop" href="#otc-def.REF.horwich.1984.1068">Horwich et al 1984</a>] and surface residues [<a class="bk_pop" href="#otc-def.REF.shi.1998.34247">Shi et al 1998</a>], which tend to be less conserved and more tolerant to amino acid substitutions.</div></li><li class="half_rhythm"><div>About 13% of reported pathogenic variants affect <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.mohamed.2015.1229">Mohamed et al 2015</a>].</div></li><li class="half_rhythm"><div>An <i>OTC</i> promoter variant that disrupts interaction between promoter and enhancer and results in reduced levels of functional <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and protein has been reported [<a class="bk_pop" href="#otc-def.REF.luksan.2010.e1294">Luksan et al 2010</a>].</div></li><li class="half_rhythm"><div>About 12% of reported variants are structural rearrangements (deletions and duplications) within the OTC <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> that result in complete absence of functional OTC [<a class="bk_pop" href="#otc-def.REF.caldovic.2015.181">Caldovic et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.choi.2015.501">Choi et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.di_stefano.2015.203">Di Stefano et al 2015</a>, <a class="bk_pop" href="#otc-def.REF.gallant.2015.249">Gallant et al 2015</a>].</div></li><li class="half_rhythm"><div>There are no prevalent, population-specific <i>OTC</i> pathogenic variants (i.e., no <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>).</div></li></ul><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The human <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> encodes a pre-protein that is 354 amino acids long (<a href="/protein/NP_000522.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000522.3</a>) [<a class="bk_pop" href="#otc-def.REF.horwich.1984.1068">Horwich et al 1984</a>]. On import into mitochondria, a 32-amino-acid mitochondrial targeting peptide is cleaved off resulting in a mature protein consisting of 322 amino acids with a predicted molecular weight of 36 kd.</p><p>Functional OTC is a homotrimer with three active sites that are shared between adjacent subunits [<a class="bk_pop" href="#otc-def.REF.shi.1998.34247">Shi et al 1998</a>]. OTC catalyzes formation of citrulline from ornithine and carbamylphosphate in the liver and small intestine [<a class="bk_pop" href="#otc-def.REF.brusilow.2001">Brusilow &#x00026; Horwich 2001</a>, <a class="bk_pop" href="#otc-def.REF.yamaguchi.2006.626">Yamaguchi et al 2006</a>]. The only known function of OTC in the human body is synthesis of citrulline, either as an intermediate of the urea cycle or a precursor of arginine biosynthesis [<a class="bk_pop" href="#otc-def.REF.brusilow.2001">Brusilow &#x00026; Horwich 2001</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants that affect <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> result either in a defective <i>OTC</i> transcript or reduced levels of functional transcript leading to complete absence or reduced abundance of functional OTC enzyme.</p><p>Pathogenic variants of the consensus <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> splice sequences and the last <a class="def" href="/books/n/gene/glossary/def-item/base-pair/">base pair</a> of exons 1-9 almost always result in the absence of functional <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> due to either absence of <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> mediated decay of aberrantly spliced <i>OTC</i> mRNA [<a class="bk_pop" href="#otc-def.REF.tuchman.2002.93">Tuchman et al 2002</a>].</p><p>Pathogenic variants that result in creation of novel splice sites have been found deep in <i>OTC</i> introns leading to aberrant <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> and reduced levels of functional <i>OTC</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and protein [<a class="bk_pop" href="#otc-def.REF.engel.2008.292">Engel et al 2008</a>].</p><p>The effect of pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants on OTC folding and activity depends on the chemical properties of the amino acid that is replacing the original residue. Substitution of amino acids located either in the active site or the protein's hydrophobic core result in absence of functional enzyme due to either lack of enzymatic activity or inability to fold [<a class="bk_pop" href="#otc-def.REF.yamaguchi.2006.626">Yamaguchi et al 2006</a>].</p><p>Substitution of amino acids located on the surface of the OTC protein or remote from the active site result in partially functional enzyme due to either reduced stability or enzymatic activity [<a class="bk_pop" href="#otc-def.REF.yamaguchi.2006.626">Yamaguchi et al 2006</a>].</p></div></div><div id="otc-def.References"><h2 id="_otc-def_References_">References</h2><div id="otc-def.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.ahrens.1996.311">Ahrens MJ, Berry SA, Whitley CB, Markowitz DJ, Plante RJ, Tuchman M. Clinical and biochemical heterogeneity in females of a large pedigree with ornithine transcarbamylase deficiency due to the R141Q mutation. <span><span class="ref-journal">Am J Med Genet. </span>1996;<span class="ref-vol">66</span>:311–5.</span> [<a href="/pubmed/8985493" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8985493</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.arn.1990.1652">Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. A cause of postpartum coma. <span><span class="ref-journal">N Engl J Med. </span>1990;<span class="ref-vol">322</span>:1652–5.</span> [<a href="/pubmed/2342525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2342525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.ausems.1997.236">Ausems MG, Bakker E, Berger R, Duran M, van Diggelen OP, Keulemans JL, de Valk HW, Kneppers AL, Dorland L, Eskes PF, Beemer FA, Poll-The BT, Smeitink JA. Asymptomatic and late-onset ornithine transcarbamylase deficiency caused by a A208T mutation: clinical, biochemical and DNA analyses in a four-generation family. <span><span class="ref-journal">Am J Med Genet. </span>1997;<span class="ref-vol">68</span>:236–9.</span> [<a href="/pubmed/9028466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9028466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.azevedo.2003.152">Azevedo L, Stolnaja L, Tietzeova E, Hrebicek M, Hruba E, Vilarinho L, Amorim A, Dvorakova L. New polymorphic sites within ornithine transcarbamylase gene: population genetics studies and implications for diagnosis. <span><span class="ref-journal">Mol Genet Metab. </span>2003;<span class="ref-vol">78</span>:152–7.</span> [<a href="/pubmed/12618087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12618087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.bailly.2015.e146">Bailly P, Noury JB, Timsit S, Ben Salem D. Teaching NeuroImages: Ornithine transcarbamylase deficiency revealed by a coma in a pregnant woman. <span><span class="ref-journal">Neurology. </span>2015;<span class="ref-vol">85</span>:e146–7.</span> [<a href="/pubmed/26574542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26574542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.balasubramaniam.2010.34">Balasubramaniam S, Rudduck C, Bennetts B, Peters G, Wilcken B, Ellaway C. Contiguous gene deletion syndrome in a female with ornithine transcarbamylase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2010;<span class="ref-vol">99</span>:34–41.</span> [<a href="/pubmed/19783189" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19783189</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.batshaw.2001.s46">Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:S46–54.</span> [<a href="/pubmed/11148549" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11148549</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.batshaw.1986.236">Batshaw ML, Msall M, Beaudet AL, Trojak J. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. <span><span class="ref-journal">J Pediatr. </span>1986;<span class="ref-vol">108</span>:236.</span> [<a href="/pubmed/3944708" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3944708</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.batshaw.2014.127">Batshaw ML, Tuchman M, Summar M, Seminara J, et al.  A longitudinal study of urea cycle disorders. <span><span class="ref-journal">Mol Genet Metab. </span>2014;<span class="ref-vol">113</span>:127–30.</span> [<a href="/pmc/articles/PMC4178008/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4178008</span></a>] [<a href="/pubmed/25135652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25135652</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.benari.2010.292">Ben-Ari Z, Dalal A, Morry A, Pitlik S, Zinger P, Cohen J, Fattal I, Galili-Mosberg R, Tessler D, Baruch RG, Nuoffer JM, Largiader CR, Mandel H. Adult-onset ornithine transcarbamylase (OTC) deficiency unmasked by the Atkins' diet. <span><span class="ref-journal">J Hepatol. </span>2010;<span class="ref-vol">52</span>:292–5.</span> [<a href="/pubmed/20031247" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20031247</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.berry.2001.s56">Berry GT, Steiner RD. Long-term management of patients with urea cycle disorders. <span><span class="ref-journal">J Pediatr. </span>2001;<span class="ref-vol">138</span>:S56.</span> [<a href="/pubmed/11148550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11148550</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.bowling.1999.452">Bowling F, McGown I, McGill J, Cowley D, Tuchman M. Maternal gonadal mosaicism causing ornithine transcarbamylase deficiency. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">85</span>:452–4.</span> [<a href="/pubmed/10405441" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10405441</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.brusilow.2001">Brusilow SW, Horwich AL. Urea cycle enzymes. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. <em>The Metabolic &#x00026; Molecular Bases of Inherited Diseases.</em> Chap 85. 8 ed. New York, NY: McGraw-Hill; 2001:1909-63.</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.brusilow.1996.127">Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. <span><span class="ref-journal">Adv Pediatr. </span>1996;<span class="ref-vol">43</span>:127–70.</span> [<a href="/pubmed/8794176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8794176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.burlina.1992.707">Burlina AB, Ferrari V, Dionisi-Vici C, Bordugo A, Zacchello F, Tuchman M. Allopurinol challenge in children. <span><span class="ref-journal">J Inherit Metab Dis. </span>1992;<span class="ref-vol">15</span>:707–12.</span> [<a href="/pubmed/1434508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1434508</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.caldovic.2015.181">Caldovic L, Abdikarim I, Narain S, Tuchman M, Morizono H. Genotype-phenotype correlations in ornithine transcarbamylase deficiency: a mutation update. <span><span class="ref-journal">J Genet Genomics. </span>2015;<span class="ref-vol">42</span>:181–94.</span> [<a href="/pmc/articles/PMC4565140/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4565140</span></a>] [<a href="/pubmed/26059767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26059767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.celik.2011.1052">Celik O, Buyuktas D, Aydin A, Acbay O. Ornithine transcarbamylase deficiency diagnosed in pregnancy. <span><span class="ref-journal">Gynecol Endocrinol. </span>2011;<span class="ref-vol">27</span>:1052–4.</span> [<a href="/pubmed/21736537" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21736537</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.chiong.2007.418">Chiong MA, Bennetts BH, Strasser SI, Wilcken B. Fatal late-onset ornithine transcarbamylase deficiency after coronary artery bypass surgery. <span><span class="ref-journal">Med J Aust. </span>2007;<span class="ref-vol">186</span>:418–9.</span> [<a href="/pubmed/17437397" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17437397</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.choi.2015.501">Choi JH, Lee BH, Kim JH, Kim GH, Kim YM, Cho J, Cheon CK, Ko JM, Lee JH, Yoo HW. Clinical outcomes and the mutation spectrum of the OTC gene in patients with ornithine transcarbamylase deficiency. <span><span class="ref-journal">J Hum Genet. </span>2015;<span class="ref-vol">60</span>:501–7.</span> [<a href="/pubmed/25994866" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25994866</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.clancy.1991.222">Clancy RR, Chung HJ. EEG changes during recovery from acute severe neonatal citrullinemia. <span><span class="ref-journal">Electroencephalogr Clin Neurophysiol. </span>1991;<span class="ref-vol">78</span>:222.</span> [<a href="/pubmed/1707794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1707794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.deardorff.2008.498">Deardorff MA, Gaddipati H, Kaplan P, Sanchez-Lara PA, Sondheimer N, Spinner NB, Hakonarson H, Ficicioglu C, Ganesh J, Markello T, Loechelt B, Zand DJ, Yudkoff M, Lichter-Konecki U. Complex management of a patient with a contiguous Xp11.4 gene deletion involving ornithine transcarbamylase: a role for detailed molecular analysis in complex presentations of classical diseases. <span><span class="ref-journal">Mol Genet Metab. </span>2008;<span class="ref-vol">94</span>:498–502.</span> [<a href="/pmc/articles/PMC2572572/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2572572</span></a>] [<a href="/pubmed/18524659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18524659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.dionisivici.2002.321">Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, Uziel G, Abeni D. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. <span><span class="ref-journal">J Pediatr. </span>2002;<span class="ref-vol">140</span>:321–7.</span> [<a href="/pubmed/11953730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11953730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.di_stefano.2015.203">Di Stefano C, Lombardo B, Fabbricatore C, Munno C, Caliendo I, Gallo F, Pastore L. Oculo-facio-cardio-dental (OFCD) syndrome: the first Italian case of BCOR and co-occurring OTC gene deletion. <span><span class="ref-journal">Gene. </span>2015;<span class="ref-vol">559</span>:203–6.</span> [<a href="/pubmed/25620158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25620158</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.dolman.1988.10">Dolman CL, Clasen RA, Dorovini-Zis K. Severe cerebral damage in ornithine transcarbamylase deficiency. <span><span class="ref-journal">Clin Neuropathol. </span>1988;<span class="ref-vol">7</span>:10.</span> [<a href="/pubmed/3370859" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3370859</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.engel.2008.292">Engel K, Nuoffer JM, M&#x000fc;hlhausen C, Klaus V, Largiad&#x000e8;r CR, Tsiakas K, Santer R, Wermuth B, H&#x000e4;berle J. Analysis of mRNA transcripts improves the success rate of molecular genetic testing in OTC deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2008;<span class="ref-vol">94</span>:292–7.</span> [<a href="/pubmed/18440262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18440262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.gallant.2015.249">Gallant NM, Gui D, Lassman CR, Yong WH, Teitell M, Mandelker D, Lorey F, Martinez-Agosto JA, Quintero-Rivera F. Novel liver findings in ornithine transcarbamylase deficiency due to Xp11.4-p21.1 microdeletion. <span><span class="ref-journal">Gene. </span>2015;<span class="ref-vol">556</span>:249–53.</span> [<a href="/pubmed/25434494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25434494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.gao.2015.474.e1">Gao J, Gao F, Hong F, Yu H, Jiang P. Hyperammonemic encephalopathy in a child with ornithine transcarbamylase deficiency due to a novel combined heterozygous mutations. <span><span class="ref-journal">Am J Emerg Med. </span>2015;<span class="ref-vol">33</span>:474.e1–3.</span> [<a href="/pubmed/25227973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25227973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.gr_newald.2004.179">Gr&#x000fc;newald S, Fairbanks L, Genet S, Cranston T, H&#x000fc;sing J, Leonard JV, Champion MP. How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency? <span><span class="ref-journal">J Inherit Metab Dis. </span>2004;<span class="ref-vol">27</span>:179–86.</span> [<a href="/pubmed/15159648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15159648</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.gyato.2004.80">Gyato K, Wray J, Huang ZJ, Yudkoff M, Batshaw ML. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">55</span>:80–6.</span> [<a href="/pubmed/14705115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14705115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.h_berle.2012.32">H&#x000e4;berle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, Karall D, Martinelli D, Crespo PS, Santer R, Servais A, Valayannopoulos V, Lindner M, Rubio V, Dionisi-Vici C. Suggested guidelines for the diagnosis and management of urea cycle disorders. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span>:32.</span> [<a href="/pmc/articles/PMC3488504/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3488504</span></a>] [<a href="/pubmed/22642880" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22642880</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.h_berle.2003.649">H&#x000e4;berle J, Koch HG. Cultured fibroblasts as a tool for improvement of molecular analysis in ornithine transcarbamylase (OTC) deficiency. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">21</span>:649.</span> [<a href="/pubmed/12754713" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12754713</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.hall.2014.889">Hall PL, Marquardt G, McHugh DM, Currier RJ, Tang H, Stoway SD, Rinaldo P. Postanalytical tools improve performance of newborn screening by tandem mass spectrometry. <span><span class="ref-journal">Genet Med. </span>2014;<span class="ref-vol">16</span>:889–95.</span> [<a href="/pmc/articles/PMC4262759/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4262759</span></a>] [<a href="/pubmed/24875301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24875301</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.honeycutt.1992.666">Honeycutt D, Callahan K, Rutledge L, Evans B. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy. <span><span class="ref-journal">Neurology. </span>1992;<span class="ref-vol">42</span>:666.</span> [<a href="/pubmed/1549234" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1549234</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.horwich.1984.1068">Horwich AL, Fenton WA, Williams KR, Kalousek F, Kraus JP, Doolittle RF, Konigsberg W, Rosenberg LE. Structure and expression of a complementary DNA for the nuclear coded precursor of human mitochondrial ornithine transcarbamylase. <span><span class="ref-journal">Science. </span>1984;<span class="ref-vol">224</span>:1068–74.</span> [<a href="/pubmed/6372096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6372096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.hu.2007.126">Hu WT, Kantarci OH, Merritt JL 2nd, McGrann P, Dyck PJ, Lucchinetti CF, Tippmann-Peikert M. Ornithine transcarbamylase deficiency presenting as encephalopathy during adulthood following bariatric surgery. <span><span class="ref-journal">Arch Neurol. </span>2007;<span class="ref-vol">64</span>:126–8.</span> [<a href="/pubmed/17210820" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17210820</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.ituk.2012.90">Ituk U, Constantinescu OC, Allen TK, Small MJ, Habib AS. Peripartum management of two parturients with ornithine transcarbamylase deficiency. <span><span class="ref-journal">Int J Obstet Anesth. </span>2012;<span class="ref-vol">21</span>:90–3.</span> [<a href="/pubmed/22138526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22138526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.jalan.2004.1338">Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. <span><span class="ref-journal">Gastroenterology. </span>2004;<span class="ref-vol">127</span>:1338–46.</span> [<a href="/pubmed/15521003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15521003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.jalan.1999.1164">Jalan R, Olde Damink SW, Deutz NE, Lee A, Hayes PC. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. <span><span class="ref-journal">Lancet. </span>1999;<span class="ref-vol">354</span>:1164–8.</span> [<a href="/pubmed/10513710" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10513710</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.keegan.2003.259">Keegan CE, Martin DM, Quint DJ, Gorski JL. Acute extrapyramidal syndrome in mild ornithine transcarbamylase deficiency: Metabolic stroke involving the caudate and putamen without metabolic decompensation. <span><span class="ref-journal">Eur J Pediatr. </span>2003;<span class="ref-vol">162</span>:259.</span> [<a href="/pubmed/12647200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12647200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.kendall.1983.28">Kendall BE, Kingsley DP, Leonard JV, Lingam S, Oberholzer VG. Neurological features and computed tomography of the brain in children with ornithine carbamoyl transferase deficiency. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1983;<span class="ref-vol">46</span>:28–34.</span> [<a href="/pmc/articles/PMC1027260/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1027260</span></a>] [<a href="/pubmed/6842197" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6842197</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.keskinen.2008.1412">Keskinen P, Siitonen A, Salo M. Hereditary urea cycle diseases in Finland. <span><span class="ref-journal">Acta Paediatr. </span>2008;<span class="ref-vol">97</span>:1412–9.</span> [<a href="/pubmed/18616627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18616627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.krivitzky.2009.96">Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. <span><span class="ref-journal">Pediatr Res. </span>2009;<span class="ref-vol">66</span>:96–101.</span> [<a href="/pmc/articles/PMC2746951/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2746951</span></a>] [<a href="/pubmed/19287347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19287347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.le_o.1995.593">Le&#x000e3;o M. Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency. <span><span class="ref-journal">Neurology. </span>1995;<span class="ref-vol">45</span>:593–4.</span> [<a href="/pubmed/7898728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7898728</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.leonard.2004.s74">Leonard JV, McKiernan PJ. The role of liver transplantation in urea cycle disorders. <span><span class="ref-journal">Mol Genet Metab. </span>2004;<span class="ref-vol">81</span>:S74.</span> [<a href="/pubmed/15050978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15050978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.lichterkonecki.2013.354">Lichter-Konecki U, Nadkarni V, Moudgil A, Cook N, Poeschl J, Meyer MT, Dimmock D, Baumgart S. Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">109</span>:354–9.</span> [<a href="/pubmed/23791307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23791307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.lipskind.2011.682">Lipskind S, Loanzon S, Simi E, Ouyang DW. Hyperammonemic coma in an ornithine transcarbamylase mutation carrier following antepartum corticosteroids. <span><span class="ref-journal">J Perinatol. </span>2011;<span class="ref-vol">31</span>:682–4.</span> [<a href="/pubmed/21956151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21956151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.luksan.2010.e1294">Luksan O, Jirsa M, Eberova J, Minks J, Treslova H, Bouckova M, Storkanova G, Vlaskova H, Hrebicek M, Dvorakova L. Disruption of OTC promoter-enhancer interaction in a patient with symptoms of ornithine carbamoyltransferase deficiency. <span><span class="ref-journal">Hum Mutat. </span>2010;<span class="ref-vol">31</span>:E1294–303.</span> [<a href="/pubmed/20127982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20127982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.majoie.2004.32">Majoie CB, Mourmans JM, Akkerman EM, Duran M, Poll-The BT. Neonatal citrullinemia: comparison of conventional MR, diffusion-weighted, and diffusion tensor findings. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2004;<span class="ref-vol">25</span>:32–5.</span> [<a href="/pubmed/14729525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14729525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.marcus.2008.395">Marcus N, Scheuerman O, Hoffer V, Zilbershot-Fink E, Reiter J, Garty BZ. Stupor in an adolescent following Yom Kippur fast, due to late-onset ornithine transcarbamylase deficiency. <span><span class="ref-journal">Isr Med Assoc J. </span>2008;<span class="ref-vol">10</span>:395–6.</span> [<a href="/pubmed/18605371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18605371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.matsuda.1991.85">Matsuda I, Nagata N, Matsuura T, Oyanagi K, Tada K, Narisawa K, Kitagawa T, Sakiyama T, Yamashita F, Yoshino M. Retrospective survey of urea cycle disorders: Part 1. Clinical and laboratory observations of thirty-two Japanese male patients with ornithine transcarbamylase deficiency. <span><span class="ref-journal">Am J Med Genet. </span>1991;<span class="ref-vol">38</span>:85–9.</span> [<a href="/pubmed/2012137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2012137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.maestri.1999.268">Maestri NE, Clissold D, Brusilow SW. Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis. <span><span class="ref-journal">J Pediatr. </span>1999;<span class="ref-vol">134</span>:268.</span> [<a href="/pubmed/10064660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10064660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.mcbryde.2004.536">McBryde KD, Kudelka TL, Kershaw DB, Brophy PD, Gardner JJ, Smoyer WE. Clearance of amino acids by hemodialysis in argininosuccinate synthetase deficiency. <span><span class="ref-journal">J Pediatr. </span>2004;<span class="ref-vol">144</span>:536–40.</span> [<a href="/pubmed/15069407" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15069407</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.mccullough.2000.313">McCullough BA, Yudkoff M, Batshaw ML, Wilson JM, Raper SE, Tuchman M. Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype. <span><span class="ref-journal">Am J Med Genet. </span>2000;<span class="ref-vol">93</span>:313–9.</span> [<a href="/pubmed/10946359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10946359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.mendezfigueroa.2010.775">Mendez-Figueroa H, Lamance K, Sutton VR, Aagaard-Tillery K, Van den Veyver I. Management of ornithine transcarbamylase deficiency in pregnancy. <span><span class="ref-journal">Am J Perinatol. </span>2010;<span class="ref-vol">27</span>:775–84.</span> [<a href="/pubmed/20458665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20458665</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.mohamed.2015.1229">Mohamed S, Hamad MH, Kondkar AA, Abu-Amero KK. A novel mutation in ornithine transcarbamylase gene causing mild intermittent hyperammonemia. <span><span class="ref-journal">Saudi Med J. </span>2015;<span class="ref-vol">36</span>:1229–32.</span> [<a href="/pmc/articles/PMC4621731/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4621731</span></a>] [<a href="/pubmed/26446336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26446336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.morgan.1987.886">Morgan HB, Swaiman KF, Johnson BD. Diagnosis of argininosuccinic aciduria after valproic acid&#x02013;induced hyperammonemia. <span><span class="ref-journal">Neurology. </span>1987;<span class="ref-vol">37</span>:886.</span> [<a href="/pubmed/3106853" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3106853</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.msall.1984.1500">Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies. <span><span class="ref-journal">N Engl J Med. </span>1984;<span class="ref-vol">310</span>:1500–5.</span> [<a href="/pubmed/6717540" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6717540</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.mustafa.2006.586">Mustafa A, Clarke JT. Ornithine transcarbamoylase deficiency presenting with acute liver failure. <span><span class="ref-journal">J Inherit Metab Dis. </span>2006;<span class="ref-vol">29</span>:586.</span> [<a href="/pubmed/16802108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16802108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.nagata.1991.477">Nagata N, Matsuda I, Matsuura T, Oyanagi K, Tada K, Narisawa K, Kitagawa T, Sakiyama T, Yamashita F, Yoshino M. Retrospective survey of urea cycle disorders: Part 2. Neurological outcome in forty-nine Japanese patients with urea cycle enzymopathies. <span><span class="ref-journal">Am J Med Genet. </span>1991;<span class="ref-vol">40</span>:477–81.</span> [<a href="/pubmed/1746614" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1746614</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.oechsner.1998.680">Oechsner M, Steen C, St&#x000fc;renburg HJ, Kohlsch&#x000fc;tter A. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1998;<span class="ref-vol">64</span>:680–2.</span> [<a href="/pmc/articles/PMC2170080/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2170080</span></a>] [<a href="/pubmed/9598692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9598692</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.oexle.2006a.204">Oexle K. Biochemical data in ornithine transcarbamylase deficiency (OTCD) carrier risk estimation: logistic discrimination and combination with genetic information. <span><span class="ref-journal">J Hum Genet. </span>2006a;<span class="ref-vol">51</span>:204–8.</span> [<a href="/pubmed/16453063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16453063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.oexle.2006b.241">Oexle K. Calculation of the reliability of the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency. <span><span class="ref-journal">J Inherit Metab Dis. </span>2006b;<span class="ref-vol">29</span>:241.</span> [<a href="/pubmed/16601906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16601906</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.panlaqui.2008.1922">Panlaqui OM, Tran K, Johns A, McGill J, White H. Acute hyperammonemic encephalopathy in adult onset ornithine transcarbamylase deficiency. <span><span class="ref-journal">Intensive Care Med. </span>2008;<span class="ref-vol">34</span>:1922–4.</span> [<a href="/pubmed/18651132" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18651132</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.pinner.2010.361">Pinner JR, Freckmann ML, Kirk EP, Yoshino M. Female heterozygotes for the hypomorphic R40H mutation can have ornithine transcarbamylase deficiency and present in early adolescence: a case report and review of the literature. <span><span class="ref-journal">J Med Case Rep. </span>2010;<span class="ref-vol">4</span>:361.</span> [<a href="/pmc/articles/PMC2997096/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997096</span></a>] [<a href="/pubmed/21070677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21070677</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.plum.1982">Plum F, Posner JB. <em>The Diagnosis of Stupor and Coma</em>. 3 ed. Oxford, UK: Oxford University Press; 1982.</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.prasun.2015.782">Prasun P, Altinok D, Misra VK. Ornithine transcarbamylase deficiency presenting with acute reversible cortical blindness. <span><span class="ref-journal">J Child Neurol. </span>2015;<span class="ref-vol">30</span>:782–5.</span> [<a href="/pubmed/24850570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24850570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.puppi.2012.1">Puppi J, Strom SC, Hughes RD, Bansal S, Castell JV, Dagher I, Ellis EC, Nowak G, Ericzon BG, Fox IJ, G&#x000f3;mez-Lech&#x000f3;n MJ, Guha C, Gupta S, Mitry RR, Ohashi K, Ott M, Reid LM, Roy-Chowdhury J, Sokal E, Weber A, Dhawan A. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. <span><span class="ref-journal">Cell Transplant. </span>2012;<span class="ref-vol">21</span>:1–10.</span> [<a href="/pubmed/21457616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21457616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.redonnetvernhet.2000.1008">Redonnet-Vernhet I, Rouanet F, Pedespan JM, Hocke C, Parrot F. A successful pregnancy in a heterozygote for OTC deficiency treated with sodium phenylbutyrate. <span><span class="ref-journal">Neurology. </span>2000;<span class="ref-vol">54</span>:1008.</span> [<a href="/pubmed/10691008" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10691008</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.ricciuti.1976.332">Ricciuti FC, Gelehrter TD, Rosenberg LE. X-chromosome inactivation in human liver: Confirmation of X-linkage of ornithine transcarbamylase. <span><span class="ref-journal">Am J Hum Genet. </span>1976;<span class="ref-vol">28</span>:332.</span> [<a href="/pmc/articles/PMC1685051/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1685051</span></a>] [<a href="/pubmed/941900" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 941900</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.rowe.1986.541">Rowe PC, Newman SL, Brusilow SW. Natural history of symptomatic partial ornithine transcarbamylase deficiency. <span><span class="ref-journal">N Engl J Med. </span>1986;<span class="ref-vol">314</span>:541.</span> [<a href="/pubmed/3945292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3945292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.rubenstein.1990.754">Rubenstein JL, Johnston K, Elliott GR, Brusilow SW. Haloperidol-induced hyperammonaemia in a child with citrullinaemia. <span><span class="ref-journal">J Inherit Metab Dis. </span>1990;<span class="ref-vol">13</span>:754.</span> [<a href="/pubmed/2246861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2246861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.r_egger.2014.21">R&#x000fc;egger CM, Lindner M, Ballhausen D, Baumgartner MR, Beblo S, Das A, Gautschi M, Glahn EM, Gr&#x000fc;nert SC, Hennermann J, Hochuli M, Huemer M, Karall D, K&#x000f6;lker S, Lachmann RH, Lotz-Havla A, M&#x000f6;slinger D, Nuoffer JM, Plecko B, Rutsch F, Santer R, Spiekerkoetter U, Staufner C, Stricker T, Wijburg FA, Williams M, Burgard P, H&#x000e4;berle J. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. <span><span class="ref-journal">J Inherit Metab Dis. </span>2014;<span class="ref-vol">37</span>:21–30.</span> [<a href="/pmc/articles/PMC3889631/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3889631</span></a>] [<a href="/pubmed/23780642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23780642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.scaglia.2004.s79">Scaglia F, Carter S, O'Brien WE, Lee B. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. <span><span class="ref-journal">Mol Genet Metab. </span>2004;<span class="ref-vol">81</span>:S79–S85.</span> [<a href="/pubmed/15050979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15050979</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.shchelochkov.2009.97">Shchelochkov OA, Li FY, Geraghty MT, Gallagher RC, Van Hove JL, Lichter-Konecki U, Fernhoff PM, Copeland S, Reimschisel T, Cederbaum S, Lee B, Chinault AC, Wong LJ. High-frequency detection of deletions and variable rearrangements at the ornithine transcarbamylase (OTC) locus by oligonucleotide array CGH. <span><span class="ref-journal">Mol Genet Metab. </span>2009;<span class="ref-vol">96</span>:97–105.</span> [<a href="/pubmed/19138872" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19138872</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.shi.1998.34247">Shi D, Morizono H, Ha Y, Aoyagi M, Tuchman M, Allewell NM. 1.85-A resolution crystal structure of human ornithine transcarbamoylase complexed with N-phosphonacetyl-L-ornithine. Catalytic mechanism and correlation with inherited deficiency. <span><span class="ref-journal">J Biol Chem. </span>1998;<span class="ref-vol">273</span>:34247–54.</span> [<a href="/pubmed/9852088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9852088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.sotogutierrez.2011.708">Soto-Gutierrez A, Tafaleng E, Kelly V, Roy-Chowdhury J, Fox IJ. Modeling and therapy of human liver diseases using induced pluripotent stem cells: how far have we come? <span><span class="ref-journal">Hepatology. </span>2011;<span class="ref-vol">53</span>:708–11.</span> [<a href="/pmc/articles/PMC3033754/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3033754</span></a>] [<a href="/pubmed/21274892" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21274892</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.takanashi.2003.390">Takanashi J, Barkovich AJ, Cheng SF, Kostiner D, Baker JC, Packman S. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2003;<span class="ref-vol">24</span>:390–3.</span> [<a href="/pubmed/12637287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12637287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.thakur.2006.273">Thakur V, Rupar CA, Ramsay DA, Singh R, Fraser DD. Fatal cerebral edema from late-onset ornithine transcarbamylase deficiency in a juvenile male patient receiving valproic acid. <span><span class="ref-journal">Pediatr Crit Care Med. </span>2006;<span class="ref-vol">7</span>:273–6.</span> [<a href="/pubmed/16575347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16575347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.tuchman.1992.836">Tuchman M. The clinical, biochemical, and molecular spectrum of ornithine transcarbamylase deficiency. <span><span class="ref-journal">J Lab Clin Med. </span>1992;<span class="ref-vol">120</span>:836–50.</span> [<a href="/pubmed/1453106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1453106</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.tuchman.2002.93">Tuchman M, Jaleel N, Morizono H, Sheehy L, Lynch MG. Mutations and polymorphisms in the human ornithine transcarbamylase gene. <span><span class="ref-journal">Hum Mutat. </span>2002;<span class="ref-vol">19</span>:93–107.</span> [<a href="/pubmed/11793468" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11793468</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.tuchman.2008.397">Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, Diaz GA, Seashore MR, Lee HS, McCarter RJ, Krischer JP, Batshaw ML, et al.  Cross-sectional multicenter study of patients with urea cycle disorders in the United States. <span><span class="ref-journal">Mol Genet Metab. </span>2008;<span class="ref-vol">94</span>:397–402.</span> [<a href="/pmc/articles/PMC2640937/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2640937</span></a>] [<a href="/pubmed/18562231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18562231</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.tuchman.1995.67">Tuchman M, Matsuda I, Munnich A, Malcolm S, Strautnieks S, Briede T. Proportions of spontaneous mutations in males and females with ornithine transcarbamylase deficiency. <span><span class="ref-journal">Am J Med Genet. </span>1995;<span class="ref-vol">55</span>:67–70.</span> [<a href="/pubmed/7702100" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7702100</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.tuchman.1998.40">Tuchman M, Morizono H, Rajagopal BS, Plante RJ, Allewell NM. The biochemical and molecular spectrum of ornithine transcarbamylase deficiency. <span><span class="ref-journal">J Inherit Metab Dis. </span>1998;<span class="ref-vol">21</span> Suppl 1:40–58.</span> [<a href="/pubmed/9686344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9686344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.tuchman.1989.77">Tuchman M, Tsai MY, Holzknecht RA, Brusilow SW. Carbamyl phosphate synthetase and ornithine transcarbamylase activities in enzyme-deficient human liver measured by radiochromatography and correlated with outcome. <span><span class="ref-journal">Pediatr Res. </span>1989;<span class="ref-vol">26</span>:77–82.</span> [<a href="/pubmed/2771513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2771513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.vaquero.2007.528">Vaquero J, Butterworth RF. Mild hypothermia for the treatment of acute liver failure--what are we waiting for? <span><span class="ref-journal">Nat Clin Pract Gastroenterol Hepatol. </span>2007;<span class="ref-vol">4</span>:528–9.</span> [<a href="/pubmed/17909531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17909531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.vargha.2012.60">Vargha R, M&#x000f6;slinger D, Wagner O, Golej J. Venovenous hemodiafiltration and hypothermia for treatment of cerebral edema associated with hyperammonemia. <span><span class="ref-journal">Indian Pediatr. </span>2012;<span class="ref-vol">49</span>:60–2.</span> [<a href="/pubmed/22318103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22318103</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.wakiya.2012.404">Wakiya T, Sanada Y, Urahashi T, Ihara Y, Yamada N, Okada N, Ushijima K, Otomo S, Sakamoto K, Murayama K, Takayanagi M, Hakamada K, Yasuda Y, Mizuta K. Impact of enzyme activity assay on indication in liver transplantation for ornithine transcarbamylase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">105</span>:404–7.</span> [<a href="/pubmed/22264779" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22264779</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.wang.2012a.203">Wang L, Morizono H, Lin J, Bell P, Jones D, McMenamin D, Yu H, Batshaw ML, Wilson JM. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. <span><span class="ref-journal">Mol Genet Metab. </span>2012a;<span class="ref-vol">105</span>:203–11.</span> [<a href="/pmc/articles/PMC3270700/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3270700</span></a>] [<a href="/pubmed/22133298" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22133298</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.wang.2010.118">Wang L, Wang H, Bell P, McCarter RJ, He J, Calcedo R, Vandenberghe LH, Morizono H, Batshaw ML, Wilson JM. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. <span><span class="ref-journal">Mol Ther. </span>2010;<span class="ref-vol">18</span>:118–25.</span> [<a href="/pmc/articles/PMC2839210/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2839210</span></a>] [<a href="/pubmed/19861950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19861950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.wang.2012b.404">Wang L, Wang H, Morizono H, Bell P, Jones D, Lin J, McMenamin D, Yu H, Batshaw ML, Wilson JM. Sustained correction of OTC deficiency in spf(ash) mice using optimized self-complementary AAV2/8 vectors. <span><span class="ref-journal">Gene Ther. </span>2012b;<span class="ref-vol">19</span>:404–10.</span> [<a href="/pmc/articles/PMC3321078/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3321078</span></a>] [<a href="/pubmed/21850052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21850052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.whitelaw.2001.36">Whitelaw A, Bridges S, Leaf A, Evans D. Emergency treatment of neonatal hyperammonaemic coma with mild systemic hypothermia. <span><span class="ref-journal">Lancet. </span>2001;<span class="ref-vol">358</span>:36–8.</span> [<a href="/pubmed/11454378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11454378</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.wilson.2012.263">Wilson JM, Shchelochkov OA, Gallagher RC, Batshaw ML. Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2012;<span class="ref-vol">105</span>:263–5.</span> [<a href="/pmc/articles/PMC3273986/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3273986</span></a>] [<a href="/pubmed/22129577" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22129577</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.wong.2012.525">Wong DA. Ornithine transcarbamylase deficiency: are carrier females suitable donors? <span><span class="ref-journal">Pediatr Transplant. </span>2012;<span class="ref-vol">16</span>:525–7.</span> [<a href="/pubmed/22672071" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22672071</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.yamaguchi.2006.626">Yamaguchi S, Brailey LL, Morizono H, Bale AE, Tuchman M. Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:626–32.</span> [<a href="/pubmed/16786505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16786505</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.yamanouchi.2002.91">Yamanouchi H, Yokoo H, Yuhara Y, Maruyama K, Sasaki A, Hirato J, Nakazato Y. An autopsy case of ornithine transcarbamylase deficiency. <span><span class="ref-journal">Brain Dev. </span>2002;<span class="ref-vol">24</span>:91–4.</span> [<a href="/pubmed/11891099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11891099</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.yang.2016.334">Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, Yu H, Xu C, Morizono H, Musunuru K, Batshaw ML, Wilson JM. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. <span><span class="ref-journal">Nat Biotechnol. </span>2016;<span class="ref-vol">34</span>:334–8.</span> [<a href="/pmc/articles/PMC4786489/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4786489</span></a>] [<a href="/pubmed/26829317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26829317</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.yorifuji.1998.349">Yorifuji T, Muroi J, Uematsu A, Tanaka K, Kiwaki K, Endo F, Matsuda I, Nagasaka H, Furusho K. X-inactivation pattern in the liver of a manifesting female with ornithine transcarbamylase (OTC) deficiency. <span><span class="ref-journal">Clin Genet. </span>1998;<span class="ref-vol">54</span>:349–53.</span> [<a href="/pubmed/9831349" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9831349</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="otc-def.REF.zecavati.2008">Zecavati N, Lichter-Konecki U, Singh R, Crawford J, Seltzer R, Gropman A. Seizures in urea cycle disorders (UCDs): An under-recognized symptom in patients outside of the acute metabolic phase. Philadelphia, PA: American Society of Human Genetics 58th Annual Meeting; 2008.</div></li></ul></div></div><div id="otc-def.Chapter_Notes"><h2 id="_otc-def_Chapter_Notes_">Chapter Notes</h2><div id="otc-def.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 April 2016 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>29 August 2013 (me) Review posted live</div></li><li class="half_rhythm"><div>31 December 2012 (ul-k) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK154378</span><span class="label">PMID: <a href="/pubmed/24006547" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">24006547</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ofd1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/chrom17-lis/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK154378&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK154378/?report=reader">PubReader</a></li><li><a href="/books/NBK154378/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK154378" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK154378" style="display:none" title="Cite this Page"><div class="bk_tt">Lichter-Konecki U, Caldovic L, Morizono H, et al. Ornithine Transcarbamylase Deficiency. 2013 Aug 29 [Updated 2016 Apr 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK154378/pdf/Bookshelf_NBK154378.pdf">PDF version of this page</a> (562K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#otc-def.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#otc-def.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#otc-def.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#otc-def.Genetically_Related_Allelic_Diso" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#otc-def.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#otc-def.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#otc-def.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#otc-def.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#otc-def.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#otc-def.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#otc-def.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5009[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">OTC</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3049902" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3049902" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3049902" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3049902" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22649802" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Camacho J, Rioseco-Camacho N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301503" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sloan JL, Carrillo N, Adams D, Venditti CP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301631" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Citrullinemia Type I</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Citrullinemia Type I<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Quinonez SC, Thoene JG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301668" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia B</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia B<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Konkle BA, Huston H, Nakaya Fletcher S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21634085" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Phosphorylase Kinase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Herbert M, Goldstein JL, Rehder C, Austin S, Kishnani PS, Bali DS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=24006547" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=24006547" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040df239a66ee2ba66d34b">Ornithine Transcarbamylase Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Ornithine Transcarbamylase Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:33:39-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B54BBE03FB6F10000000006A90268&amp;ncbi_session=CE8B54BBE040DF21_1705SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK154378%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK154378&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK154378/&amp;ncbi_pagename=Ornithine Transcarbamylase Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B54BBE040DF21_1705SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>